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Abstract 
Enterococci have recently emerged as important pathogens because of their 
association with nosocomial infections and their antimicrobial multiple resistance 
traits. Since the situation of enterococcal infections and their resistance in Hong 
Kong is largely unknown, we undertook a study to determine the species 
distribution and antimicrobial susceptibilities of clinical enterococcal isolates in the 
Prince of Wales Hospital from 1997 to 1998. 
A total of 498 non-replicate enterococcal isolates were studied. These 
included 397 isolates and 44 isolates from urine and bile, respectively, collected 
during the three-month period (April - June) of 1997 and 1998; and 49 isolates 
from blood, two isolates from cerebrospinal fluid and six isolates from body fluids 
from April 1997 to March 1998. Our finding that the majority of enterococcal 
isolates were from urine was similar to that reported in other studies. The ability of 
polymerase chain reaction (PGR) to definitively identify enterococcal isolates to 
species level was evaluated by testing 309 isolates (which represented more than 
60% of the total isolates studied and were thus a representative collection of 
enterococcal strains) using API 20 Strep, PGR and conventional biochemical tests. 
These isolates were from urine and bile collected during April - June, 1997 and 
from blood, body fluid and cerebrospinal fluid collected during April, 1997 -
March, 1998. 
Both API 20 Strep and PCR gave the same identification results for 240 
Eriterococcus faecalis isolates, 45 E. faecium isolates and one isolate each of E. 
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^allmarum and E. casscliflavus. The remaining 69 isolates were re-identified by 
conventional biochemical tests. It was found that PGR could correctly identify 303 
isolates while API 20 Strep could only correctly identify 287 (93%) isolates, i.e., 
99% of faecalis and 57-87% of the other Enterococcus species. Thus, PGR was 
used in the identification of the remaining isolates and the identity of isolates other 
than E. faecalis was subsequently confirmed by conventional biochemical tests. 
Results indicated that 403 (81%) were E. faecalis, 11 (15%) were E. faecium and 
18 (4%) were other enterococcal species {E. gallinarum (8), E. casseliflavus (4), 
E.durans (2), E. raffinosus (3) and E. avium (1)). This distribution of clinical 
enterococcal species was similar to that found in other parts of the world. 
E. faecium isolates were more frequently resistant than E. faecalis to 
penicillin (95% versus 1%), ampicillin (87% versus 1%), high-level streptomycin 
(67% versus 36%), trimethoprim (53% versus 16%), co-trimoxazole (58% versus 
15%), rifampicin (92% versus 56%) and sparfloxacin (66% versus 8%). The 
percentage of other enterococcal species resistant to these antibiotics was in 
general similar to that of E. faecalis. Only four isolates were resistant to 
vancomycin, two were E. faecium (vancomycin MIC >16 mg/L) and one each of 
E. gallinarum and E. casseliflavus (vancomycin MIC = 8 mg/L). One of the 
vancomycin-resistant K faecium was also resistant to teicoplanin (MIC >16mg/L). 
Thus, vancomycin resistance was not a problem here as compared to the United 
States and some European countries where VRE were prevalent. Our study showed 
that an average of 15% of the enterococcal isolates were resistant to ampicillin and 
25% were resistant to high concentrations of gentamicin. If the standard regimen of 
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ampicillin plus an aminoglycoside for treating serious enterococcal infections was 
used, there would be a 1 in 4 chance of treatment failure. In general, resistance to 
antimicrobials other than vancomycin and teicoplanin of enterococci in Hong 
Kong was high as compared to that in other countries. 
A total of 47 isolates with vancomycin MICs >4 mg/L were tested for the 
presence of vancomycin resistance genes by PCR. One isolate each of E. faecium 
was shown to harbour vanA and vanB genes. The vanC-1 gene was found in eight 
E. gallinarum isolates and vanC-2 gene was found in two E. casseliflavus isolates. 
One hundred and twenty-four isolates with gentamicin MICs >1024 mg/L were 
subjected to PCR to detect for the presence of the aac(6')-aph(2") gene. Only four 
isolates did not harbor the gene. None of the ampicillin-resistant enterococci 
(ampicillin MIC >8mg/L) produced P-lactamase. Pulsed-field gel electrophoresis 
(PFGE) of iS'mal-restricted DNA of multi-resistant enterococci showed that they 














faecalis，四十五株爲 E.faecium 及E. gallinarum 禾口 E. casseliflavus 各一株， 
餘下之菌種由於被API 20 Strep和聚合霉鏈反應分別鑒定成不同種，所以需要 
以發酵測試重新鑒別這些菌種。結果顯示，聚合霉鏈反應能準確地璧別了三 
百零三株腸球菌，而API 20 Strep只能準確靈別出二百八十七株（93%)分。API 
20 Strep能準確地鑒定出"％的faecalis，但用來璧定其它的腸球菌則只有 








比對以下抗生素耐藥，青霉素（ 9 5 % 對 1 % ) ，氨卞西林（ 8 7 % 對 
1%)，鏈霉素（67%對36%)，曱氧卞氧嚼卩定(53%對16%)，復方新諾明（58% 
對15%)，利福平（92%對56%)及sparfloxacin (6 6 %對8%)�其它腸球菌的耐 
藥程度跟faecalis的大致相若。只有四株菌種對萬古霉素呈耐藥，其中兩 
株爲 E. faecium (MIC >16 mg/L)及 E. gallinarum, E. casseliflavus 各一株 
(MIC = 8 mg/L)�而其中一株對萬古霉素呈耐藥的E. faecium對teicoplanin 
同樣呈耐藥（MIC>16mg/L)� 
在對萬古霉素(MIC >4 mg/L)呈耐藥的四十七株腸球菌裏，發現只有 
兩椒./縱/謂含有丽及丽•基因°另夕 f，有八椒.gal l inarium^^vanCl 
的基因及兩株cos^se/zyZaz/s含有的基因。這些基因分別利用特定弓[ 
物在聚合霉鏈反應中測試出來。我們也利用聚合霉鏈反應測試了一百二十四 
株對慶大霉素呈高度耐藥(MIC >1024 mg/L)的菌種。其中只有四株沒有存 
在對慶大霉素呈耐藥的基因_c6，~apli2�。而在對氨卞西林（MIC >8 mg/L) 
耐藥的菌種中，並沒有一只製造內酰胺酶（/5-lactamase)�另外，又用核 
酸內切酶消化屬於對多種抗生素呈耐藥的腸球菌的脫氧核糖核酸， 
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1. Introduction 
1.1. Taxonomy of enterococci 
The term "enterococcus" was first used by Thiercelin in 1899 to describe 
those bacteria seen in pairs or short chains in faeces (Murray, 1990). With the 
development of Lancefield's streptococcal grouping system and the discovery of 
group D antigen in enterococci in the 1930s, the concept of enterococci as salt 
tolerant group D streptococci was established (RuofF et al, 1990). In 1937, 
Sherman divided the serological group D streptococci into two groups: I) 
'enterococcus' that included Streptococcus faecalis and S. faecium, II) 'non-
enterococcus' that included S. bovis and S. equinus (Murray, 1990). 
Recently, the development and widespread use of molecular techniques in 
taxonomic analysis have led to a significant change in the classification of 
enterococci. In 1970, Kalina suggested to put S. faecalis and S. faecium and their 
subspecies into a separate genus - Enterococcus (Kalina, 1970). His suggestion was 
based on their cellular arrangement and phenotypic characteristics. However, the 
genus Entercoccus was not established until 1987 when Schleifer and Kilpper-Balz 
noted that S. faecalis and S. faecium were not related to streptococci by DNA-
DNA and DNA-rRNA hybridization (Schleifer & Kilpper-Balz，1984 & 1987). 
There were initially only two species in this genus - E. faecalis and E. faecium but 
now, eleven more species are described. These include E. durans, E. avium, E. 
casseliflavus, E. malodoratus, E. gallinarum, E. mundtii, E. raffinosus, E. 
solitarius, E. hirae, E. pseudoavium and E. flavascens. 
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1.2. Natural habitat of enterococci 
Enterococci are found naturally in the environment such as soil and water 
and in animals and insects. In humans and in animals, enterococci are present as 
normal flora in the gastrointestinal and genital tracts. E. faecalis is amongst the 
most common bacteria found in the human gut while E. faecium may also be 
commonly found (Facklam & Teixeira，1999). 
1.3. General characteristics of the genus Enterococcus 
Enterococci are gram-positive, facultative anaerobic cocci that occur singly 
or are arranged in pairs or short chains. The optimum growth temperature is 35°C 
but most of them can grow at a temperature range of 10°C and 45°C. They are 
similar to streptococci in that they do not have cytochrome enzymes and so are 
catalase negative. All enterococci can grow in 6.5% sodium chloride broth and 
hydrolyse esculin in the presence of 40% bile salts. In addition, they can hydrolyse 
L-pyrrolidonyl-P-naphthylamide (PYR) and produce leucine aminopeptidase (LAP). 
1.4. Identification to species level of enterococci 
The identification of enterococci to species level is often required for 
epidemiological investigations. Enterococci are conventionally speciated using 
biochemical and physiological tests. According to Facklam and Collins (1989), 
enterococci can be differentiated into three groups based on acid formation in 
mannitol, sorbitol, and sorbose broth and hydrolysis of arginine. 
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E. avium, E. malodoratus, E. raffinosus and E. pseudoavium belong to 
group 1. They form acid in all the above three carbohydrate broths but fail to 
hydrolyze arginine. They can be further differentiated by acid formation in arabinose 
and raffinose broths. E. avium forms acid in arabinose but not in raffinose broth. E. 
malodoraus forms acid in raffinose but not in arabinose broth. E. raffinosus forms 
acid in both while E. pseudoavium does not form acid in either broths. 
Group II includes E. faecalis’ E. faecium, E. casseliflavus’ E. mundtii, E. 
flavescens and E. gallinarum. They form acid in mannitol broth and hydrolyze 
arginine but fail to form acid in sorbose broth and give variable reactions in sorbitol 
broth. Tolerance to tellurite, utilization of pyruvate, motility test and yellow 
pigment formation can be used to further differentiate them. E. faecalis is the only 
species in this group that tolerates tellurite and utilizes pyruvate. E. faecium and E. 
gallinarum have similar characteristics but they can be differentiated by motility test 
:E. faecium is non-motile but E. gallinarum is motile. E. casseliflavus, E. mundtii 
and E. flavescens produce yellow pigment. However, E. casseliflavus and E. 
flavescens are motile while E. mundtii is not. E. casseliflavus forms acid in ribose 
broth while E. flavescens does not. 
Group III includes E. durans，E. hirae and E. dispar. They can hydrolyze 
arginine but do not form acid in mannitol, sorbitol or sorbose broth. They can be 
further differentiated by the pyruvate, raffinose and sucrose tests. E. durans is 
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negative in all three tests. E. hi rem can form acid in one or both broths but does not 
utilize pyruvate. E. dispar is positive in all three tests. 
Identification of enterococci by conventional biochemical tests is often 
tedious and labour intensive. Commercial identification systems are much simpler to 
use and include API 20 Strep system, Gram Positive Identification Card of Vitex 
System, API 32 rapid Strep system (all from bioMerieux SA, Montalieu Vercieu, 
France) and RapID STR system (Innovative Diagnostic Systems, Atlanta, Ga., 
USA). Most of these systems provide results in approximately four hours. These 
systems had been evaluated and were shown to be able to accurately identify E. 
faecalis but not the other enterococcal species (KuofF & Kung, 1982; Ruoff et al, 
1982; Ruoff, 1990; Nachamkin, Lynch & Dalton, 1982; Jorgensen Crawford & 
Alexander, 1983; Appelbaum et al, 1984a, 1984b & 1986; Facklam, Rhoden & 
Smith, 1984; Facklam et al, 1985; You & Facklam，1986; Fertally & Facklam, 
1987). 
Accurate identification based on biochemical tests might be difficult to 
achieve for some species with unusual biochemical characteristics or for those that 
differ by only one or two biochemical properties (Williamson et al, 1986; Facklam 
& Collins, 1989; Ruoff ez' al, 1990; Vincent et al, 1991; Donabedian et al, 1995(a); 
Facklam, Sahm & Teixeria，1999). Examples include E. faecium with unusual 
sorbitol and sorbose fermentation characteristics (Williamson et al, 1986), E. 
gallinarum and E. casseliflavus are motile while E. faecium and E. faecalis are not, 
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and E. casseliflavus usually forms yellow pigment while E. gaUinarum does not 
(Facklam & Collins, 1989). Besides, there are some strains of E. casseliflavus that 
are motile and do not produce pigment (Vincent et a/, 1991). Recently, molecular 
biological techniques had been used to identify enterococci. These included nucleic 
acid hybridization, DNA amplification and protein analysis (penicillin binding 
proteins and whole cell profiles). 
Polymerase chain reaction (PCR) is one of the most common techniques 
used. Primers for the specific identification of E. faecalis and E. faecium have been 
designed (Dutka-Malen, Evers & Courvalin, 1995). Since the vanC-1 and vanC-
2IC-3 genes are found only in E. gallinarum and E. casseliflavus!E. flavescens, 
respectively, primers specific for vanC-1 and vanC-2l3 genes are used for the 
identification of these two species (Leclercq et al, 1992; Dutka-Malen, Evers & 
Courvalin, 1995; Clark et al’ 1998). The method was based on the specific 
detection of genes coding for D-alanine:D-alanine (D-Ala:D-Ala) ligases (ddl) 
present in all E. faecalis and E. faecium {dd\E. faecaUs and ddl^". /���respectively) but 
not in other enterococcal species (Dutka-Malen, Evers & Courvalin, 1995). The D-
ala-D-serine ligases are encoded by the intrinsic genes vanC-1 and vanC-2 or vanC-
3 found in E. gallinarum and E. casseliflavus or E. flavescens, respectively but not 
in other enterococcal species tested (Leclercq et al, 1992; Navarro & Courvalin， 
1994, Cartwright et al，1995). The van C-2 and van C-3 genes of E. casseliflavus 
and E. flavescens are almost identical (98%) and primers for van C-2 can also 
anneal to van C-3 (Navarro & Courvalin, 1994; Clark et al, 1998). Thus, PCR 
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cannot be used to distinguish these two species which are phenotypically very 
similar (Dutka-Malen，Evers & Courvalin，1995; Patel et al, 1997). 
1.5. Clinical significance of enterococci 
Enterococci are normal flora of the gut, vagina, perineum, anterior urethra 
and oral cavity (Nord & Wadstr6m, 1973; Adhami, 1982; Facklam, Sahm & 
Teixeria, 1999). They are regarded as being of low pathogenicity because they lack 
the common virulence factors such as haemolysin, aggregation substances and 
adhesives (Facklam & Teixeria, 1999; Witte, Wirth & Klare，1999). However，these 
organisms have increased in importance as nosocomial pathogens during the past 20 
years in many parts of the world. They become the second most common 
nosocomial pathogens in the United States, accounting for 10% of all hospital-
acquired infections in 1986-1989 (Schaberg, Culver & Gaynes, 1991). E. faecalis is 
the most common enterococcal species causing infections in man, followed by E. 
faecium (Silverman et al, 1998; Reinhert et al, 1999; Schouten et al, 1999). The 
other species do not frequently cause infections. From a recent report by the 
National Nosocomial Infections Surveillance (NNIS) system, enterococci were 
reported as the second most common pathogens isolated from bloodstream 
infection and the third most common pathogens isolated from urinary tract infection 
in the intensive care unit (ICU) in the United States during 1990-1999 (CDC, 
1999). 
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Most of the enterococcal infections are endogenous, that is, they are 
acquired from the patient's o � flora, and most of them are naturally resistant to 
multiple antibiotics. Thus, extensive use of broad-spectrum antimicrobial agents 
such as cephalosporins and quinolones that had no activity against enterococci was 
thought to predispose patients to the development of enterococcal infections (Spera 
& Farber, 1992; Heath, Blackmore & Gordon，1996; Hunt, 1998). However, the 
clinical importance of enterococci has often been questioned except when they are 
isolated from urine, blood or other sterile sites (Murray，1990; Maki & Agger, 
1988; Low et al, 1994). 
Enterococci can cause various diseases, the most common being urinary 
tract infections, followed by intra-abdominal or pelvic wound infections, 
bacteraemia, endocarditis and neonatal meningitis. Enterococci account for about 
10% of all urinary tract infections (Felmingham et al, 1992). They are second to 
Escherichia coli as causes of nosocomial urinary tract infections, urinary 
catheterization or instrumentation being the important predisposing factors 
(Murray, 1990; Schaberg, Culver & Gaynes，1991; Moellering, 1992). 
Intra-abdominal or pelvic wound infections are the next most common 
infections caused by enterococci. A mixture of organisms usually causes these 
infections and the clinical significance of enterococci thus remains controversial 
(Dougherty, 1984; Nichols & Muzik, 1992). Use of a single antimicrobial agent 
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either for prophylaxis or treatment of these infections is probably an important 
predisposing factor (Low et al, 1994; Low, Willey & McGeer, 1995). 
Enterococci are the third most common cause of nosocomial bacteraemia in 
the United States in 1986-1989 (Schaberg, Culver & Gaynes，1991). More than 
40% of such bacteraemia are polymicrobial, caused by Enterococcus and one other 
microorganism and the source being mainly from the urinary tract, intra-abdominal 
or pelvic sepsis, wound or intravenous catheter (Maki & Agger, 1988; Gullberg, 
Homann & Phair’ 1989). Patients are usually elderly and have serious underlying 
diseases or immunocompromised and have prolonged hospital stay and on 
antimicrobial therapy. Mortality of patients with enterococcal bacteremia before 
VRE appeared was 33%-68% (Edmond et al, 1996(b)). However, it is interesting 
to note that mortality rate attributable to bacteremia caused by vancomycin-
susceptible enterococci (VSE) and VRE is similar, being 31% and 37%, 
respectively (Landry, Kaiser & Wenzel, 1989; Edmond et al, 1996(a)). It could be 
postulated that strains of VRE were probably not inherently more virulent than 
VSE. 
In contrast to enterococcal bacteremia, which is frequently polymicrobial, 
enterococcal endocarditis is usually not. However, it is significantly associated with 
underlying valvular heart disease. About 5% to 15% of all cases of endocarditis are 
caused by enterococci, the most common species being E. faecalis (Maki & Agger， 
1988; Murray, 1990; Johnson et a /�1998). Enterococcal endocarditis is often sub-
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acute and usually occurs in elderly men, young women and intravenous drug users 
with underlying valvular heart disease or prosthetic valves (Maki & Agger, 1988; 
Murray, 1990; Moellering, 1997). 
1.6. Clinical management of enterococcal infections 
Single-drug therapy such as penicillin, ampicillin or vancomycin is used for 
the treatment of uncomplicated enterococcal infections such as urinary tract 
infection (Anonymous, 1992). However, for serious enterococcal infections that 
require a bactericidal effect such as endocarditis, meningitis or osteomyelitis, 
treatment includes a cell wall active agent (such as penicillin, ampicillin or a 
glycopeptide) combined with an aminoglycoside (usually gentamicin or sometimes 
streptomycin) (Geraci & Martin，1954; Koenig & Kaye, 1961; Moellering, 1992; 
Murray, 1990; Hunt, 1998). 
This combination of therapy can overcome the intrinsic resistance to 
aminoglycoside of enterococci since penicillin disrupts the cell wall and increases 
the permeability of the organism to aminoglycoside thus resulting in an effective 
synergistic killing. However, strains have become resistant to high-levels of 
aminoglycosides so that such synergistic effect will be lost. With the development of 
resistance to an increasing number of antimicrobial agents, the choice of drugs for 
serious enterococcal infections has become limited (Spera & Farber, 1992; Heath, 
Blackmore & Gordon, 1996; Huycke, Sahm & Gilmore, 1998). 
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1,7. Antimicrobial susceptibilities of enterococci 
Enterococci are relatively resistant to antimicrobial agents that are usually 
used in the treatment of gram-positive infections. They are also intrinsically resistant 
to many antimicrobial agents including the p-lactams and aminoglycosides. The 
minimum inhibitory concentrations (MICs) of p-lactam drugs are relatively high as 
compared to those to streptococci, e.g. the MIC of penicillin for enterococci is 10-
to 100-fold higher than that for streptococci (Gordon et al, 1992; Low et al, 1994). 
In general, E. faecium is more resistant to antimicrobial agents than E. 
faecalis. E. faecium is less sensitive to p-lactams than E. faecalis. However, E. 
faecalis is tolerant to penicillin or ampicillin and will not be killed unless 
concentrations reach 100 mg/L or higher. Acquired ampicillin-resistance in E. 
faecalis is rare and the first ampicillin-resistant E. faecalis strain due to the 
production of P-lactamase was not isolated until early 1980s (Murray, & Mederski-
Samoraj, 1983; Gray & Pedler, 1992). Subsequently, high-level p-lactam-resistant 
enterococci dramatically increased and by the late 1980s, 8-78% of enterococci 
were ampicillin-resistant (Oster et al, 1990; Grayson, et al, 1991; Boyce et al, 
1992; Patterson et al, 1995; Landman & Quale, 1997). Recent studies showed that 
the percentage of ampicillin-resistance in E. faecalis is 0-15% and in E. faecium 
about 5-80% (Gray, Stewart & Pedler, 1991; McNamara, King & Smyth, 1995; 
Vandamme et al, 1996; Iwen et al, 1997). The percentage of antibiotic resistance in 
enterococci also varies among countries. In New Zealand, all E. faecalis strains are 
susceptible to ampicillin but 10% of E. faecium are resistant (Taylor et al, 1997). 
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However, in the United States and European countries, 20-60% of K faecium are 
resistant to ampicillin (Douboyas & Tsakris，1995; Perlada, Smulian & Cushion, 
1997; Reinert et al, 1999). 
Vancomycin-resistant enterococci (VRE) were first seen in the late 1980s in 
Europe, the United States and Australia (Anderson, Davey & Bell, 1997; 
Moellering, 1997; Bell, Paton & Turnidge, 1998; French, 1998; Hunt, 1998;). 
Subsequently, more countries reported the presence of VRE. In general, more E. 
faecium strains are resistant to glycopeptides than is E. faecalis. Besides, many 
VRE strains are also resistant to all clinically important antibiotics (CDC, 1993). In 
Asian countries, the percentage of VRE remains low. In Japan, no vanA or vanB 
genes are detected and less than 1% of low-level vancomycin-resistant enterococci 
(van C type) are seen (Hirkata et al, 1997). Recently, high-level vancomycin-
resistant enterococci were isolated in Taiwan (Hsueh et al, 1999). Although VRE 
are present in the United Kingdom and France, the incidence rate remains low 
(Leclercq, 1996; Johnson et al, 1998; Reinert et al, 1999). However, high incidence 
of VRE was reported in the United States. From the data ofNNIS, the incidence of 
VRE in hospitals has increased dramatically from 0.3% in 1989 to 8% in 1993 
(CDC, 1993). 
High-level aminoglycoside resistance (HLAR) was first described in the 
1970s in France (Hunt, 1998) and by mid-1980s, reports of HLAR in enterococci 
appeared all over the world with incidence varying from 10% to 60% (Gordon et 
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Cd, 1992; Douboyas & Tsakris, 1995; Vandamme et al, 1996; Tsakris，Pournaras & 
Douboyas, 1997; Johnson et al, 1998; Cirak & Sultan, 1998; Reinert et al, 1999; 
Papaparaskevas et al, 2000). In Asia, the percentage ofHLAR varies, being 14% in 
Thailand, 22% in Singapore, 43% in Japan and 63% in Taiwan (Tsaur et al，1993: 
Chiew & Hall, 1998). In European countries, the percentage ofHLAR is 10% to 
. . . . . . . . . . . . . . . . ,. -. . . . 
50% while in the United States, it is 10-60% (Gordon et al, 1992; Perlada, Smulian 
& Cushion, 1997; Tsakris, Pournaras & Douboyas，1997; Johnson et al, 1998; 
Reinert et al, 1999). In some other countries like Germany, Australia and Belgium， 
the percentage ofHLAR is similar in E. faecium and E. faecalis whereas in the 
United States, United Kingdom and Ireland，the percentage ofHLGR in E. faecium 
is higher than E. faecalis (McNamara, King, Smyth, 1995; Vandamme et al, 1996; 
Iwen etal, 1997; Perlada, Smulian & Cushion, 1997; Reinert et al, 1999). 
. -. -• . . . . . . . . . . • 
1.8. Antimicrobial resistance of enterococci 
Antimicrobial resistance in enterococci can be either intrinsic or acquired. 
Enterococci are intrinsically resistant to different classes of antimicrobials including 
P-lactams, clindamycin, the folate inhibitors and aminoglycosides. Resistance to P-
lactams is generally low-level and is mainly due to the low affinity of cell wall 
penicillin-binding proteins (PBPs) to these drugs (Williamson et al, 1983; 
Zighelboim-Duam & Moellering，1988; Gray & Pedler，1992). Although some p-
lactams are active, they are not bactericidal against most of the strains. 
Furthermore, cephalosporins are ineffective against the enterococci (Leclercq, 
1997). 
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Low-level aminoglycoside resistance is due to reduced uptake of drug by 
bacteria. Since aminoglycosides are highly positively charged and insoluble in 
organic solvents, they are unable to transverse the cytoplasmic membrane of 
enterococci. Besides, the anaerobic metabolism of enterococci does not favour 
transport of aminoglycosides which requires oxidative energy (Bryan, Kowand 8c 
van den Elzen, 1979). Despite their resistance to P-lactams and aminoglycosides, 
synergistic activity of the combination of these two classes of drugs has been 
demonstrated in the treatment of invasive enterococcal infections (Geraci & Martin, 
1954; Moellering & Weinberg, 1971). Enterococci are shown to be susceptible to 
trimethoprim and co-trimoxazole in vitro. However, they may utilize exogenous 
supplies of thymidine and thymine and become resistant (Murray, 1990; Gray & 
Pedler, 1992). 
In addition to their inherent antibiotic resistance, enterococci can very 
readily acquire resistance to a wide range of antimicrobial agents. Acquired 
resistance occurs either through mutation in the existing genes or through 
acquisition of new genes borne on plasmids or transposons (Murray, 1990). High-
level resistance to P-lactams can be due to acquisition of a (3-lactamase gene 
originating from staphylococci but most commonly due to an increase in the 
production of low-affinity penicillin-binding proteins (Murray, 1992; Fontena et al, 
1992). p-Lactamase-producing E. faecalis was first isolated in the early 1980s in 
the United States and later in Argentina and Lebanon (Moellering, 1992; Murray, 
1992). This type of resistance is usually plasmid-mediated and often linked with 
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high-level gentamicin resistance (Murray, 1992). E. faecium is less sensitive to 
ampicillin than E. faecalis due to differences in the PBPs. The increase in high-level 
p-lactam resistance is mainly due to overproduction of a penicillin-binding protein， 
PBP5, that has a low affinity for p-lactam drugs (Williamson et al, 1985; Herman & 
Gerding, 1991; Low, Willey & McGeer, 1995; Leclercq, 1997; Rybkine et al, 
1998). 
High-level resistance to the aminoglycosides in enterococci was first 
reported in the 1970s in France (Horodniceanu et al, 1979) and subsequently in 
many parts of the world (Murray，1990; Patterson & Zervos, 1990; Low et al, 
1994; Chiew & Hall, 1998). The spread of this resistance is usually due to the 
transfer of genes coding for aminoglycoside-modifying enzymes (AMEs). These 
genes are borne on plasmids or on transposons, some of which may be identical to 
those found in staphylococci (Patterson et al, 1988; Herman & Gerding, 1991; 
Hodel-Christian & Murray，1991; Leclercq et al, 1992; Thai et al, 1994). However, 
in some strains of E. faecalis, high-level streptomycin resistance can also be due to 
gene mutation leading to a change in the affinity of ribosomes to streptomycin 
(Eliopoulous et al, 1984). The most common AME produced by enterococci is 6，-
acetyltransferase 2" phosphotransferase (AAC(6')-APH(2")), a bifunctional 
enzyme. AAC(6')-APH(2") is the product of two AME genes, aac-6’ and aph-2，， 
which have Rised to generate a single gene. It confers resistance to all clinically 
important aminoglycosides except streptomycin (Courvalin, Carlier & Collatz， 
1980; Leclercq, 1997). Other AMEs produced by enterococci include streptomycin 
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adenylytransferase (ANT(6)), 3'-phosphotransferase (APH(3')) and 4'-
nucleotidytranferase (ANT(4，)). Strains that are resistant to high-levels of 
aminoglycosides will also be resistant to the synergistic activity of aminoglycosides 
plus cell wall active agents. Recently, another aminoglycoside resistance gene, 
aph(2’，)-Ic, coding for APH(2”)-Ic enzyme which confers moderate level of 
resistance to gentamicin (MIC = 256 mg/L) has been detected in enterococci (Chow 
et al, 1997; Tsai et al, 1998). 
Resistance to glycopeptides is due to various mechanisms and is classified as 
class A to E，based on the level of resistance to vancomycin and teicoplanin and 
whether the resistance is inducible or constitutive (Leclercq, 1988; Murray, 1990; 
Leclercq et al, 1992; Dutka-Malen, Evers & Courvalin, 1995; Free & Sahm, 1996; 
Leclercq, 1997; Moellering, 1998). Glycopeptides inhibit cell wall synthesis by 
binding to the terminal dipeptide, D-alanyl-D-alanine (D-ala-Da-ala) of 
peptidoglycan precursors at the cell surface which block this precursor from further 
participating in cell wall synthesis. Resistant strains have modified terminal 
dipeptide, which does not bind to glycopeptides. 
Class A strains have inducible resistance to high-levels of both vancomycin 
(MIC >64 mg/L) and teicoplanin (MIC >16 mg/L) due to the presence of a vanA 
gene (Low, Willey & McGeer, 1995; Murray, 1997; Hunt, 1998). This gene is 
present on a plasmid and can be transferred to other Gram-positive bacteria (Gray 
& Pedler, 1992; Murray, 1997; French, 1998). It encodes a D-alanine-D-alanine 
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ligase of modified specificity that results in the synthesis of cell wall precursors 
ending in D-alanyl-D-lactate (D-ala-D-lac) instead of D-ala-D-ala, the target site for 
vancomycin (Arthur & Courvalin, 1993; Arthur, Reynolds & Courvalin, 1996; 
Murray, 1997). 
Class B strains show moderate resistance to vancomycin (MIC 4 - 1024 
mg/L) but remain susceptible to teicoplanin (MIC <1 mg/L) and have the vanB 
gene. This resistance phenotype is induced by vancomycin only and is transferable 
by conjugation in certain strains (Quintiliani, Evers & Courvalin，1993; Arthur, 
Reynolds & Courvalin, 1996; Murray, 1997; Leclercq, 1997). 
Class C strains show constitutive low-level resistance to vancomycin (MIC 
>8 to 32 mg/L) but are susceptible to teicoplanin. The resistance is a special 
characteristic of E. gallinarum (yanC-l genotype), E. casseliflavus (vanC-2 
genotype) and E. flavescens (yanC-3 genotype). Since transferability of vanC gene 
has not been demonstrated, it is thought that the gene might be borne on the 
chromosome (Leclercq et al, 1992; Navarro & Courvalin, 1994; Murray, 1997; 
Toye et al, 1997; Clark et al, 1998). 
Two new vancomycin resistance phenotypes have been discovered recently. 
VanD gene was reported in 1997 in an E. faecium isolate constitutively resistant to 
vancomycin and to low-level teicoplanin (Perichon, Reynolds & Courvalin，1997). 
VanE gene was detected in an E. faecalis isolate that was resistant to low-levels of 
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vancomycin but not to teicoplanin (Fines et al, 1999). The sequence of the gene is 
55% identical to van C-1 gene (Fines et al, 1999). 
Enterococci can also acquire resistance to other antibiotics such as the 
macrolides, choramphenicol, tetracycline and quinolones. Resistance to macrolides 
is due to the presence of a gene of coding for rRNA methylase that methylates 23 S 
rRNA resulting in reduced ribosomal binding and subsequent resistance to 
lincoamide and streptogramin B (Murray, 1990; French, 1998). Chloramphenicol 
resistance in enterococci is usually due to the production of chloramphenicol 
acetyltransferase and is plasmid-mediated (Murray, 1990). Strains that are resistant 
to tetracycline harbour genes such as tetM and tetNi\\?iX protect the ribosomes from 
inhibition by tetracycline (Leclerq, 1997). Quinolone resistance in enterococci is due 
to chromosomal mutation that alters the subunit A of DNA gyrase (French, 1998). 
1.9. Molecular typing of enterococci 
Traditional methods for the typing of enterococci include biotyping, 
antibiotic resistance profiling, serotyping, phage typing and bacteriocin typing. 
Biotyping, antibiotic resistance profiling and serotyping are shown to be 
insufficiently discriminatory for most epidemiological studies (Murray, 1990). 
Although phage typing and bacteriocin typing are superior, the procedures involved 
are laborious and special reagents and continuous maintenance are required 
(Murray，1990). 
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Recently, various molecular techniques such as plasmid profile analysis, 
ribotyping and DNA fingerprinting have been used in the typing of enterococci. 
Plasmid analysis, whereby the number and size of plasmids of strains are compared, 
has been used in the investigation of outbreaks caused by E. faecalis with high-level 
resistance to gentamicin (Huycke, Spiegel & Gilmore, 1991) and vancomycin-
resistant E. faecium (Clark et al, 1993). However, this method can only be applied 
to strains containing plasmids. Furthermore, plasmids may be gained or lost from 
the strains and are therefore not stable markers. 
DNA fingerprinting involves digesting genomic DNA with restriction 
endonucleases that have multiple recognition sites within the genome and then 
analysing the patterns of restricted fragments obtained after separation on agarose 
gels electrophoretically. However, large numbers of fragments are generated 
making interpretation difficult (Hall et al, 1992). This problem can be solved by 
using a probe which hybridizes with some of the fragments. A probe commonly 
used for this purpose is a rRNA probe. Its discriminatory power depends on the 
number and location of rRNA operons and the restriction enzymes used. Restriction 
enzymes such as EcoRl, Hindlll and Pstl have been used for ribotyping of 
enterococcal strains (Gordillo, Singh & Murray, 1993; Bates, Jordens & Griffiths, 
1994). Although hybridization patterns were found to be reproducible and 
relatively easy to interpret, ribotyping is time-consuming and laborious. 
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Another method to facilitate interpretation of DNA fragment patterns is to 
separate the fragments by pulsed-field gel electrophoresis (PFGE). PFGE separates 
DNA molecules by alternating electric fields (Birren & Lai，1993; Kaufmann & Pitt, 
1994; Tenover et al, 1995). Under the influence of the first electric field, DNA 
molecules elongate in the direction of the field and migrate into the gel. When the 
first field is removed and a second field is applied, at an angle to the first electric 
field, the DNA coil changes conformation and reorientates before migrating in the 
direction of the second field. Reorientation and separation is proportional to the size 
of DNA fragments. Numerous studies have used PFGE to separate restricted DNA 
fragments for typing of enterococci (Toye et al, 1997; Bonten et al，1998; Fridkin 
et al, 1998; van den Braak et al, 1998 & 1999; Liassine et al, 1998). Various 
enzymes have been used but the most frequently used one is Smal (Donabedian et 
al, 1995; Green et al, 1995; Reinert et al, 1999). Both contour-clamped 
homogenous electric field (CHEF) electrophoresis and field inversion gel 
electrophoresis (FIGE) can be used for PFGE. CHEF electrophoresis is performed 
in a special electrophoretic equipment (which is quite expensive) whereby 
alternating electric fields at 120° angle are provided while FIGE can be performed 
in a conventional electrophoretic chamber which provides inversion of electric 
current at 180° (Goering, 1993). The two techniques have been evaluated and 
shown to yield comparable results (Green ef al, 1995). Despite the high cost in 
performing PFGE in CHEF equipment, it is more widely used, probably because of 
the better quality of the gel image and better separation of bands of >250 kb in size 
(Green et ai 1995). 
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PCR-based fingerprinting methods have also been used in the 
epidemiological studies of enterococci. The principle of this method is that when 
primers bind appropriately to specific regions of DNA of the test isolates, strain-
specific amplification products may be obtained. Primers used may be specific such 
as in PCR-ribotyping where specific primers are used to amplify the 16S - 23S 
rRNA intergenic spacer region or non-specific as random amplified polymorphic 
DNA (RAPD) analysis whereby single primers of arbitrary sequence are used to 
anneal to multiple sites on the DNA under low-stringency conditions to produce a 
number of amplified DNA products (Williams et al, 1990; Welsh & McClelland, 
1990; Castano-Anolles, Bassam & Gresshoff, 1991; Kostman et al, 1995; Barbier et 
al, 1996). 
Prokaryotic genomes contain many families of highly repeated DNA 
sequences such as ERIC (enterobacterial repetitive intergenic consensus) sequences 
(Hulton, Higgins & Sharp, 1991), REP (repetitive extragenic palindromic) elements 
or palindromic units (PU) (Gilson et al, 1987) and BOX elements (Martin et al, 
1992). Primers specific to these elements can be used in PCR for fingerprinting 
different bacterial species (Versalovic, Koeuth & Lupski, 1991). This particular 
type of PCR is known as repetitive sequence-based PCR or REP-PCR. Malathum 
and colleagues (1998) used REP-PCR to investigate the relatedness of E. faecalis. 
The primers used are based on the BOX elements which are interspersed repetitive 
DNA sequences found in Streptococcus pneumoniae (Martin et al, 1992). Both 
clonal and epidemiologically distant strains can be discriminated using this method. 
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However, results may not be reproducible and interpretation is often difllcult, 
probably because fewer bands are generated and some products are not consistently 
visible (Malathum et al，1998). 
1.10. Epidemiological studies of enterococci 
Most epidemiological studies of enterococci have concentrated on the 
investigation of outbreaks and dissemination of vancomycin-resistant enterococci 
while studies on the general epidemiology of enterococci are much less. PFGE has 
been applied to study the relatedness of P-lactamase-producing, high-level 
gentamicin resistant E. faecalis isolated in seven years from one hospital in the 
United States (Seetulsingh et al, 1996). Results showed that there was an endemic 
clone circulating in the hospital over the 7-year period. Studies in other parts of the 
United States also showed that spread of a limited number of penicillinase-
producing strains are responsible for ampicillin-resistant enterococcal infections 
(Coudron, Markowitz & Wong, 1992; Seetulsingh et al, 1996). Bonten and 
colleagues (1996) used PFGE to demonstrate that colonization of the 
gastrointestinal tract or skin and contamination by the environment by VRE 
contribute to the spread of VRE in the hospital. Most VRE infections in hospitals 
are due to clonal spread of a single strain such as that found in South Africa (van 
Gottberg et al, 2000), Switzerland (Liassine et al, 1998) and Scotland (Nelson et 
al 2000). 
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In contrast, Malathum et al (1998) found that of their 41 E. faecalis isolates 
studied, 17 are of distinct patterns and 24 can be classified into eight groups. 
BischofF and colleagues (1999) found that four endemic strains are circulating in 
their hospital in Virginia, United States. Strains appeared and then disappeared after 
a certain period of time. They also found that more VREs are isolated in wards than 
in intensive care units (ICUs) which usually have a higher rate of isolation 
(Martone, 1998). Papaparaskevas et al (2000) also showed that there is 
considerable diversity amongst their high-level aminoglycoside-resistant (albeit 
vancomycin-sensitive) enterococcal strains. An interesting study by Suppola et al 
(1999) showed that both VRE and VSE (vancomycin-sensitive enterococci) 
isolated in their hospital are of the same type as demonstrated by PFGE. This is 
because VRE is the result of incorporation of vanA and vanB genes into an endemic 
VSE strain. 
In the study by Issack, Power & French (1996), RAPD was used in the 
typing of vancomycin-resistant E. faecium (VREF) collected from 103 patients over 
a four-year period in a London teaching hospital. The results suggest that although 
several different strains of VREF are involved, cross-infection with individual types 
does occur on some wards. In another study, VRE are collected from 10 hospitals 
in Cincinnati in Ohio during a 6-month period (Perlada, Smulan & Cushion, 1997). 
PFGE revealed that all of the E. faecium isolates with the VanB phenotype are of 
identical or closely related patterns. This suggests that there has been a clonal 
dissemination of a single strain of VanB E. faecium. Reinert et al (1999) showed 
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that other than the common intra-hospital spread of VRE, inter-hospital spread of 
VRE can also take place. Fridkin and colleagues (1998) also noted that a dominant 
VRE strain at a hospital in Massachusetts has spread to another hospital, affecting a 
large number of patients. Also, an interesting study by van den Braak et al (1998), 
on the epidemiology of VRE from patients and poultry products shows that VRE 
isolated from patients are different from those from animals. It also shows that 
spread of resistance genes borne on transposons may be more important as the 
route of dissemination of VRE than clonal spread of resistant strains. 
Recently, many studies have been performed on the epidemiology of 
nosocomial enterococcal infections especially with the increase of VRE. The 
understanding of the sources and dissemination of VRE requires the use of accurate 
typing method and PFGE was shown to be the most discriminating typing technique 
and usually considered as the "standard" for the typing of VRE (Boyle et al, 1993; 
Clark et al, 1993; Barbier et al, 1996) 
In summary, PFGE appears to be the most favourable method in terms of 
discriminatory power, reproducibility and simplicity of procedures for the 
epidemiological studies of enterococci. 
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1.11. Objectives 
Despite the increasing importance of enterococci as nosocomial pathogens 
in many parts of the world, there has been no study on the prevalence, distribution 
and antimicrobial susceptibilities of enterococci in Hong Kong. This study therefore 
aimed to: 
• Determine the susceptibility of enterococci isolated in the Prince of Wales 
Hospital to antimicrobial agents; 
• Evaluate methods for the identification of different enterococcal species; 
• Determine the mechanisms of antibiotic resistance using biochemical and 
molecular methods; and 
• Determine the degree of genetic relatedness of multiply-resistant enterococci by 
analysis of restriction DNA fragments using pulsed-field gel electrophoresis. 
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2. Materials and Methods 
2.1. Collection of isolates 
All non-duplicate enterococcal isolates (the first isolate from each patient) 
obtained from blood culture，cerebrospinal fluid and body fluids during April, 1997 
-March, 1998 and from urine and bile during April - June of 1997 and 1998 in the 
Prince of Wales Hospital were collected. Isolates were stored on nutrient agar 
slopes (Oxoid, Basingstoke, Hampshire, England) at ambient temperature and in 
bead system (PROTECT Technical Service, Heywood, Lancashire, UK) at -20°C. 
Bacteria were recovered from storage by subculturing on blood agar. 
2.2. Quality control strains 
The control strains used in this study were E. faecium AIB40 (yanA gene), 
E. faecalis ATCC 51299 (vanB gene), E. gallinarum MB 39 (yanC-1 gene), E. 
casseliflavus ATCG 25788 (yanC-2 gene；, E. faecalis ATCC 29212, S. aureus 
ATCC 29213 and S. aureus 77040101 (AAC6'-APH2"). 
2.3. Identification of isolates to genus level 
Isolates were identified to genus level by the following screening tests: gram 
staining, microscopic morphology, production of catalase, growth on and 
blackening of bile-esculin agar and growth in the presence of 6.5% NaCl. 
25 
2.4. Identification of isolates to species level 
2.4.1. By commercially available biochemical method 
Isolates were identified to species level using the API 20 Strep system 
(bioMerieux SA, Montalieu Vercieu, France) according to procedures 
recommended by the manufacturer. Briefly, colonies grown overnight on blood agar 
were harvested using a swab and suspended in 2 ml sterile distilled water to give a 
turbidity greater than that of a McFarland No. 4 standard (equivalent to 12 x 10^  
CFU/ml). The suspension was inoculated into wells of the strip and incubated at 
37°C for 4 to 24 hours. Results were read after addition of appropriate reagents to 
the wells and were interpreted as described in the manufacturer's insert. A seven-
digit code was generated and the identification result was read off from the API 20 
Strep Database (Version 6.0). 
2.4.2. By molecular method - multiplex PCR 
2.4.2.1. Source of primers 
Four clinically relevant enterococci: E. faecalis, E. faecium, E. gallinarum 
and E. casseliflavus!E. flavescens were identified by the multiplex PCR assay using 
four sets of oligonucleotide primers (Gibco BRL, Gaithersburg, MD, USA) based 
on published sequences (Dutka-Malen, Evers & Courvalin, 1995). Their nucleotide 
sequences are listed in Table 1. 
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Table 1. Oligonucleotide primers used in PCR for species identification of 
enterococci. 
Amplified Oligonucleotides Position PCR 
gene — product 
Pair Nucleotide sequence, 5' to 3' size (bp) 
ddhfaecaiis Entc9 +ATCAAGTACAGTTAGTCT 98-116 941 
EntelO -ACGATTCAAAGCTAACTG 1038-1021 
ddlE.faecium Eiitcll +TAGAGACATTGAATAATGCC NA* 50 
Entcl2 -TCGAATGTGCTACAATC NA* 
vanC-1 Entcl3 +GGTATCAAGGAAACCTC 246-272 822 
Entc 14 -CTTCCGCC ATC AT AGCT 1067-1051 
vanC-2, EntclS +CTCCTACGATTCTCTTG 455-486 439 
vanC-3 
Entcl6 -GAGGCAAGACCTTTAAG 885-869 
* NA = Not available 
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2.4.2.2. Extraction of bacterial DNA 
Two to four overnight isolated colonies on blood agar were selected and 
suspended in 500 |li1 of sterile distilled water. The suspension was heated at 94�C 
for 8 minutes using a heating block (TRU TEMP™ DNA micro-heating system, 
Robbins Scientific, Sunnyvale, CA., USA), centrifliged at 4,000 g (Biofuge 22R, 
Heraeus Sepatech, Osterode, Germany) for 5 minutes and DNA in the supernatant 
was used as template for PCR. 
2.4.2.3. Multiplex PCR 
The 25 |il-volume PCR mixture contained sterile distilled water, Ix PCR 
buffer, 0.2 mM of dNTP, 2 mM of MgCl]，0.5 |iM each of the eight primers, 0.5 
, .. • . . . . . . . . . . . . . . . .. • • 
unit of Taq polymerase (all from Gibco) and 3 |il of template DNA. DNA 
amplification was performed on a thermal cycler (PTC-100™ Programmable 
Thermal Controller, MJ Research Inc., Watertown, MA, USA) according to the 
following protocol: denaturation at 94°C for 2 minutes, then 30 cycles at 94°C for 
60s, 53�C for 60s and 72�C for 60s, and a final extension reaction at 72�C for 10 
minutes. 
2.4.2.4. Analysis of PCR products by agarose gel electrophoresis 
PCR products (5|il) with l^il of 6x loading buffer (0.25 % bromophenol 
blue and 15 % Ficoll type 400, Sigma) were subjected to electrophoresis (GIBCO 
BRL Horizontal gel electrophoresis apparatus) on 1.5% agarose gel (Sigma) in Ix 
Tris-borate-EDTA (TBE) buffer (44.5mM Tris, 44.5mM boric acid, ImM EDTA, 
28 
Sigma) at 70V for 1 hour. The molecular size marker used was //ac-Ill-digested 
(t)xl74 phage DNA (Amersham Pharmacia Biotech AB, Uppsala, Sweden). The gel 
was stained by ethidium bromide (1 |ig/ml) for 15 minutes and washed with distilled 
water. It was visualized under ultraviolet (UV) illumination and was photographed 
using a gel documentation system (Image Master YDS, Pharmacia). 
2.4.3. By conventional biochemical methods 
Isolates giving discrepant results using the two identification methods were 
re-identified by conventional biochemical methods according to the published 
scheme of Facklam and Collins (1989). The tests performed included acidification 
of 1% mannitol, sorbitol, arabinose and raffinose in heart infiision broth (Difco, 
Detroit, ME, USA) with bromocresol purple (BDH, Poole, England) as the 
indicator, deamination of arginine in Moellers decarboxylase medium (Becton 
Dickinson Microbiology Systems, Cockeysville, MD, USA) and formation of 
yellow pigment after overnight incubation on trypticase soya agar (Oxoid). Motility 
was determined by motility testing medium (Difco). All tests were incubated at 
37°G except for motility that was incubated at 30�C for up to five days. 
2.5. Antimicrobial susceptibility testing 
The minimal inhibitory concentrations (MICs) of different antimicrobial 
agents were determined by the agar dilution method according to the guidelines of 
the National Committee for Clinical Laboratory Standards (NCCLS, 1997). The 
following drugs were tested: penicillin (P), ampicillin (A), gentamicin (G), 
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streptomycin (St), erythromycin (E)，trimethoprim (Tm), sulfamethoxazole, 
chloramphenicol (C), rifampicin (Rif), sparfloxacin (Spx) (RP64206) from Sigma 
Chemical Co., St Louis, Mo., USA, vancomycin (V) (Abbott Labs, North Chicago, 
IL, USA), teicoplanin (Tei) (Marion Merrell Dow, Cincinnati, OH, USA) and 
quinupristin/dalfopristin (RP59500) (Rhone-Poulenc Rorer, Cologne, Germany). 
2.5.1. Preparation of antimicrobial agent stock solution 
The following formula was used to determine the amount of antibiotic 
powder and volume of diluent of an antibiotic stock solution: 
. .. . . . . - . . - . ... 
Weight of = Volume of diluent (ml) x Concentration of stock solution (|Lig/ml) 
antibiotic (mg) Potency of antibiotic (idg/mg) 
The antimicrobial stock solutions were aliquoted into sterile polypropylene 
or polyethylene vials and stored at -60°C or below. 
2.5.2. Preparation of agar medium 
Mueller-Hinton agar (Oxoid) was used except for testing trimethoprim and 
co-trimoxazole when Mueller-Hinton agar with 5% lysed horse blood was used. 
Appropriate volumes of serial two-fold dilutions of antibiotics were added to 
molten agar to give the final concentrations. The molten agar was then mixed 
thoroughly and poured into a petri dish on a leveled surface. The agar was allowed 
to solidify at room temperature and either used immediately (drugs such as p-
lactams and tetracyclines which deteriorate rapidly) or stored in sealed plastic bags 
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at 4 � C - 8 � C for up to 5 days. The plates were equilibrated to room temperature 
before use. Drug-free Mueller-Hinton plates were used as controls. 
2.5.3. Preparation of inoculum and inoculation of plates 
The inoculum was prepared by emulsifying a few overnight colonies of a 
single type in 3 ml of normal saline. The turbidity was adjusted to match that of a 
0.5 McFarland standard (equivalent to approximately 10^ CFU/ml). The suspension 
was then diluted 10-fold with saline to give a concentration of lO? CFU/ml. 
Antibiotic and control plates were inoculated with this inoculum using a multipoint 
inoculator (MIC 2000，Dynatech Instrument, Inc., CA, USA) which delivered 
approximately 1 [i\ giving a final inoculum of lO* CFU/spot. The following control 
strains were included in each experiment: ATCC 29212 (E. faecalis), ATCC 51299 
(E. faecalis), KTCC 25788 {E. casseliflavus), AIB40 {E. faecium), AIB39 (R 
gallinarum) and ATCC 29213 (S. aureus). 
2.5.4. Incubation and reading of plates 
The inoculated plates were left at room temperature until moisture on the 
inoculation spots was completely absorbed into the agar. The plates were inverted 
and incubated at 37°C for 16 to 20 hours. The MIC was determined as the lowest 
concentration of antimicrobial agent that completely inhibited visible growth at the 
inoculation spot. 
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The percentage of resistance was determined by the breakpoint criteria used 
to define susceptible strains based on the NCCLS MIC interpretative standards 
(1999) except for trimethoprim and co-trimoxazole (Sxt) when interpretative 
standards for urinary tract infection were used (< 8 mg/L and < 32 mg/L, 
respectively). NCCLS did not define any MIC interpretative standard for 
sparfloxacin so a breakpoint of 1 mg/L (similar to that of ciprofloxacin) was used. 
2.6. Mechanisms of antibiotic resistance 
2.6.1. Amplification of vancomycin resistance genes in enterococci by multiplex 
PCR 
2.6.1.1. Isolates 
Enterococci with vancomycin MIC > 4mg/L were selected for PCR. The 
following strains were used as controls: E. faecium AIB40 {vanA gene)，E. faecalis 
ATGC 51299 {vanB gene), E. gallinarum AIB 39 (yanC-l gene), E. casseliflavus 
ATCC 25788 {yanC-2 gene； and E. faecalis ATCC 29212 (vancomycin sensitive 
strain). 
2.6.1.2. Primers 
The oligonucleotide primers (Gibco) used were as described by Dutka-
Malen, Evers and Courvalin (1995) and Free and Sahm (1995) and are listed in 
Table 2. Acquired vancomycin resistance genotypes were identified by specific 
amplification of the vanA and vanB genes and intrinsic vancomycin resistance 
genotypes by specific amplification of the vanC-1 and vanC-2/C-S genes. 
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2.6.1.3. Extraction of bacterial DNA and PGR 
These were performed as described in sections 2.4.2.2. and 2.4.2.3. except 
that the amplification conditions were as follows: denaturation at 95°C for 3 
minutes, 30 cycles of 94�C for 60s，56�C for 60s and 72�C for 60s, and a final 
extension at 72�C for 10 minutes. PGR products were detected by agarose gel 
electrophoresis as described in section 2.4.2.4. Two PCRs were set up for each 
sample. One contained primer pairs for the detection of vanA and vanB genes (783 
and 297 bp PGR fragments, respectively) and the other contained primer pairs for 
the detection of vanC-1 and vanC-2 or vanC-3 genes (822 and 439 bp PGR 
fragments, respectively). 
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Table 2. Oligonucleotide primers for the amplification of vancomycin resistance 
genes. 
Amplified Oligonucleotide Size of PCR 
Gene Pair Nucleotide sequence, 5' to 3' product (bp) 
vanA VanAl +GCTATTCAGCTGTAGTC 783 
VanA2 -CAGCGGCCATCATACGG 
vanB VanBl +CATCGCCGTCCCCGAATTTCAAA 297 
VanB2 -GATGCGGAAGATACGGTGGCT 
vanC-1 VanCl-1 +GGTATCAAGGAAACCTC 822 
VanC 1 -2 -CTTCCGCC ATC AT AGCT 
vanC-2/3 VanC2-l +CTCCTACGATTCTCTTG 439 
VanC2-2 -CGAGCAAGACCTTTAAG 
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2.6.2. Detection of gene coding for aminoglycoside-modifying enzyme 
(AAC67APH2") by PCR 
2.6.2.1. Isolates 
All enterococci with gentamicin MIC >1024mg/L were subjected to PCR. S. 
aureus ATCC 29213 was used as a negative control and S. aureus 77040101 which 
produced AAC67APH2" was used as a positive control. Twenty strains with 
gentamicin MIC <256 mg/L were also selected randomly for testing. 
2.6.2.2. Primers 
The oligonucleotide primers (Gibco) used were as reported by van de 
Klundert and Yliegenthart (1993) and are listed in Table 3. The 16S rRNA primers 
were used as internal control and absence of the rRNA amplified signals indicated 
failure of the PCR. 
2.6.2.3. Extraction of bacterial DNA and PCR 
These were performed as described in sections 2.4.2.2. and 2.4.2.3. except 
that the reaction mixture and PCR conditions were as follows: 25|Lil-volume PCR 
mixture contained sterile distilled water, Ix PCR buffer, 0.2 mM of dNTP, 2 mM of 
MgCl2, 0.6 jiM of four primers, 0.5 unit of Taq polymerase and 2 |li1 of template 
DNA; denaturation at 95°G for 3 minutes, 32 cycles of 94�C for 60s，56�C for 60s 
and 72�C for 60s，and a final extension at 72°C for 10 minutes. PCR products were 
detected by agarose gel electrophoresis as described in section 2.4.2.4. 
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Table 3. Oligonucleotide primers for amplification of gene coding for the 
aminoglycoside modifying enzyme AAC67APH2". 
Amplified Oligonucleotide Position Size of 
Gene ~ ~ ~ ~ ^ " “ PCR 
Pair Sequence, 5' to 3' product  
(bp) 
16SrRNA Rrsl +GGATTAGATACCCTGGTAGTCC 775-796 320 
Rrs2 -TCGTTGCGGGACTTAACCCAAC 1095-1074 
aacA/aphD Amel +CCAAGAGCAATAAGGGCATA 423-442 220 
(AAC67APH2") 
Ame2 -CACTATCATAACCACTACCG 643-624 
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2.6.3. Detection of P-lactamase in enterococci 
Enterococci with ampicillin MICs >8 mg/L were screened for the presence 
of P-lactamase with cefinase disc (BBL Microbiology Systems, Cockeysville, MD, 
USA) according to the manufacturer's instruction. Briefly, the disc was moistened 
with distilled water and a few colonies were placed on it. A yellow to red colour 
change within 5 minutes on the area where the culture was applied indicated a 
positive reaction and the presence of P-lactamase. 
2.7. To study the genetic relatedness of multi-resistant enterococci by pulsed-
field gel electrophoresis (PFGE) 
Multi-resistant enterococci were selected for molecular typing by pulsed-
field gel electrophoresis (PFGE). Genomic DNA was prepared as described 
(Murray, 1990; Donabedian et al, 1995; Vandamme et al, 1996; Perlada, Smulian & . 
Cushion, 1997; Toye et al, 1997) but with modifications. All reagents used were 
from Sigma Chemical Co. unless indicated otherwise. 
2.7.1. Incorporation of chromosomal DNA into agarose plugs 
About half a loopfiil of overnight colonies on blood agar was suspended in 
500 |Lil SE buffer (75 mM NaCl, 25 mM EDTA, pH 7.5). Cells were pelleted by 
centrifliging at 4,000 g for 10 minutes, washed three times with SE buffer and 
finally resuspended in 500 fil SE buffer. Equal volumes of bacterial suspension and 
2% Seaplaque GTG low-melting-agarose (FMC, Rockland, MA’ USA) in SE buffer 
at 56°C were mixed. The mixture was dispensed into plug moulds (Bio-Rad, 
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Hercules, CA, USA) and kept at 4°C for at least 30 minutes or until the agarose 
was set. The plugs were incubated overnight at 37�C in 3 ml of lysis buffer (6 mM 
Tris HCl, 1 M NaCl, 100 mM EDTA, 0.5% Brij 58, 0.2% sodium deoxycholate, 
0.5% sodium lauroyl sarcosine, 1 mg of lysozome per ml), replaced by 3 ml of 
proteolysis buffer (0.5 M EDTA-pH 9.5，1% N-lauroyl sarcosine and 100 |Lig/ml of 
proteinase K (GIBCO BRL)) and were incubated for a further 24 hours at 56�C. 
The plugs were then washed three times with 5 ml of TE buffer at 4 � C and used 
immediately or stored at 4°C in TE buffer. 
2.7.2. Digestion of chromosomal DNA in agarose plugs with restriction enzyme 
Smal 
A portion of a plug was cut and placed in an Eppendorf tube containing 100 
|j,l restriction buffer (Ix, supplied with the restriction enzyme). The plug was kept at 
4 � C for 2 hours. The buffer was replaced with fresh restriction buffer (Ix) 
containing 20 lU of Smal (Amersham Pharmacia) and was incubated for 16-20 
hours at 30�C. 
2.7.3. Pulsed-field gel electrophoresis 
The plugs were loaded into wells of a 1.2% agarose gel (Seakem gold 
agarose, FMC) in 0.5x TBE buffer and electrophoresed on a pulsed-field gel 
electrophoresis equipment (CHEF MAPPER, Bio-Rad). The parameters for 
electrophoresis were 6 V/cm for 20 hours, pulse times ramped from 5 to 35 s, 
ramping factor: linear, included angle: 120° and temperature was 14°C. 
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Bacteriophage X DNA-PFGE markers (Amersham Pharmacia) were used as size 
marker. After electrophoresis，the gels were stained in ethidium bromide, washed in 
distilled water and photographed under UV illumination by a gel documentation 
system (Image Master VDS, Pharmacia). 
2.7.4. Cluster analysis 
The PFGE patterns were compared by the Dice coefficient (Arbeit, 1999) 
and cluster analysis performed by the unweighted pair group method with arithmetic 
average (Sneath, 1972) using the GelCompar 4.0 software (Applied Maths, 
Kortrijk, Belgium). Patterns with a Dice coefficient of>0.9 (i.e. of >90% similarity) 
were highly similar and likely to be epidemiologically related (Arbeit, 1999). These 
patterns were therefore grouped as a single group. 
2.7.5. Date analysis 
The chi square test was used for statistical analysis. 
2.8. Research plan 
All Enterococcus species isolated from urine and bile during the three-
month period (April to June) in 1997 and 1998 and from blood, body fluids and 
cerebrospinal fluid from April 1997 to March 1998 collected from patients in the 
Prince of Wales Hospital and which survived were included in the study. 
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1. Evaluation of polymerase chain reaction (PCR) for the identification of 
enterococci. 
All enterococci isolated in 1997 were identified by PCR and API 20 Strep and 
the identities confirmed by biochemical tests. 
2. Identification of all enterococcal isolates. 
Isolates subsequently collected in 1998 were identified using PCR only and all 
non-i；. faecalis isolates were re-identified by biochemical tests. 
3. Antimicrobial susceptibility testing. 
The agar dilution method (NCCLS, 1997) was used to determine minimal 
inhibitory concentrations (MICs) of 13 antimicrobial agents to Enterococcus 
species. 
4. Mechanisms of antibiotic resistance. 
Isolates resistant to vancomycin (MIC > 4mg/L) or high-levels of gentamicin 
(MIC >1024 mg/L) were subjected to PCR for detection of van or aac(6')-aph(2") 
genes, respectively. Isolates resistant to ampicillin (MIC >8mg/L) were tested for 
the production of p-lactamase. 
40 
5. Epidemiology of enterococci. 
Multi-resistant enterococcal isolates were typed by pulsed-field gel 
electrophoresis (PFGE) and restriction patterns analyzed using the GelCompar 
program. 
. . . • • . . . . . . • ‘ - • 
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3. Results 
A total of 498 non-duplicate isolates obtained from April to June in 1997 
from urine and bile and April in 1997 to March in 1998 from blood, body fluids 
and cerebrospinal fluid (CSF) were studied. These included 49 isolates from blood 
cultures, six from body fluids (four from ascitic fluid and two from pleural fluid), 
two from CSF, 44 from bile (26 in 1997 and 18 in 1998) and 397 from urine (225 
in 1997 and 172 in 1998). 
3.1. Identification of enterococci by API 20 Strep and PCR 
Three hundred and nine isolates from urine and bile in 1997 and blood 
cultures, body fluids and CSF from 1997 to 1998 were identified to species level 
using API 20 Strep, PCR and conventional tests. The remaining 189 isolates were 
identified by multiplex PCR supplemented by conventional tests. 
Two hundred and ninety-eight strains were identified with an excellent to 
good API identification score using API 20 Strep system (Table 4). These were E. 
faecalis (246), E. faecium (47), E. avium (2), E. casseliflavus (2) and E. gallinarum 
(1). However, 11 strains could only be identified to genus level. The identification 
ranged from low discrimination to good. These included E. faecium or E. 
gallinarum (3), E. gallinarum or E. faecalis (2), E. gallinarum or E. faecium, E. 
faecalis or E. durans, E. durans or E. faecium, E. faecalis or E. faecium (1 each) 
andE. avium ox Aerococcus (2). 
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Table 4. Identification of enterococci by API 20 Strep 
API identification score API identification No. of strains (%) 
Excellent to good E. faecalis 246 (82.5) 
E. faecium 47(15.8) 
E. avium 2 (0.7) 
E. casseliflavus 2 (0.7) 
E. gallinarum 1 (0.3) 
Total 298 (100) 
Low discrimination/ E. faecalis/E. faecium 1 (9.1) 
good to genus level only E. faecalis/E. durans 1 (9.1) 
E. faecium/E. gallinarum 3 (27.2) 
E. gallinarum/ E. faecalis 2(18.2) 
E. gallinarum/ E. faecium 1 (9.1) 
E. durans/E. faecium 1 (9.1) 
E. avium/Aerococcus 2* (18.2) 
Total 11 (100) 
the two isolates identified as either E. avium or Aerococcus were finally 
confirmed to be E. avium due to their ability to grow at 45°C. 
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The API Database suggested several additional tests for definite 
identification of these isolates. For example, formation of yellow pigment was used 
to differentiate E. casseliflavus from E. faecium and E. gallinarum. Growth at 
45°C was used to differentiate E. avium from Aerococcus: E. avium could grow at 
45�C while Aerococcus could not. By this test, the two isolates that were identified 
as E. avium or Aerococcus were finally identified as E. avium. For the other 
strains, either no complementary test was suggested by the API Database or the 
suggested tests were not available in our laboratory. Thus, their final identifications 
were according to the results suggested by API Database. 
Three hundred and three isolates could be identified to species level by 
multiplex PGR, PCR products of the expected sizes (Table 1) were obtained 
(Figure 1). Two hundred and forty-three isolates were identified as E. faecalis, 52 
as E. faecium, five as E. gallinarum and three as E. casseliflavus. Six isolates could 
not be identified as no amplified product was produced after PCR. This indicated 
that they were probably enterococcal species other than E. faecalis, E. faeeium, E. 
gallinarum and E. casseliflavus. 
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Figure 1. Agarose gel electrophoresis of amplified products after multiplex PCR 
using species-specific primers for enterococci. 
1 2 3 4 5 6 7 8 9 10 11 12 13 M 
Amplified products from isolates were contained in lanes 1 - 9 . Lanes 1，2, 5 - 9: 
E. faecalis. Lane 3: E. gallinarum. Lane 4: E. faecium. Amplified product from 
control strains were contained in lanes 10 —13. Lane 10: E. casseliflavus (ATCC 
25788), Lane 11: E. gallinarum (AIB39), Lane 12: E. faecium (AIB40), Lane 13: 
E. faecalis (ATCC 51299). Size marker ((|)X174 phage DNA - Haem digest) in 
lane M. 
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Both API 20 Strep and PCR gave the same results for 287 isolates (Table 
5). These included 240 E. faecalis isolates, AS E. faecium isolates and one isolate 
each of E. gallinarum and E. casseliflavus. Their identities were confirmed by 
conventional tests except for those identified as E. faecalis. Twenty-two isolates 
gave discrepant results. To confirm the identities of these 22 isolates, acid 
formation of sorbitol and arabinose broths, motility and formation of yellow 
pigment were performed (Facklam & Collins，1989) (Table 5). For E. durans, 
deamination of arginine and acid formation of mannitol and arabinose broth were 
performed and for E. avium, deamination of arginine and acid formation of 
mannitol, sorbitol, arabinose and raffinose broths were performed (Table 5). Five 
isolates that were identified as E. faecalis by API were finally identified as E. 
faecium because of its ability to form acid from arabinose broth but not from 
sorbitol broth. One isolate that was identified as E. faecalis by API was confirmed 
to be E. gallinarium because of its ability to form acid from arabinose broth but not 
from sorbitol broth, motility and absence of pigmentation. One isolate that was 
identified as either E. faecalis or E. faecium was finally identified as E. faecalis 
due to its ability to form acid from both arabinose and sorbitol broths. 
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Table 5. Comparison of API 20 Strep, PCR and conventional method for the 
identification of 309 isolates of enterococci.  
Identification results by 
API 20 Strep pCR Conventional method Final ID No. 
E. faecalis E. faecalis ND K faecalis 240-
E. faecalis E. faecium E. faecium (Sor- Ara+) E. faecium 5* 
K faecalis E. gallinarum E. gallinarum (Sor-Ara+Mot+Pig-) E. gallinarium 1 * 
E. faecalis/ E. faecalis E. faecalis (Sor+ Ara-) K faecalis 1* 
E. faecium 
E, faecalis/ N e g a t i v e E. durans (Arg+ Man- Sor- Ara- Raf-) E. durans 1 
E. durans 
E. faecium E. faecium E. faecium (Sor- Ara+) E. faecium 4 5 八 * 
E. faecium E. faecalis E. faecalis (Sor+ Ara-) E. faecalis 2* 
E. gallinarum E. gallinarum E. gallinarum (Sor-Ara+Mot+Pig-) E. gallinarum 1八 * 
E. gallinarum/ E. gallinarum E. gallinarum (Sor-Ara+Mot+Pig-) E. gallinarum 1 * .J 
E. faecalis 丨 
E. gallinarum/ E. faecium E. faecium (Sor-Ara+Mot-Pig-) E. faecium 1* 1 
E. faecalis 
E. gallinarum/ E. faecium E. faecium (Sor- Ara+ Mot- Pig-) E. faecium 1* ” 
E. faecium 1 
E. gallinarum/ K gallinarum E. gallinarium (Sor-Ara+Mot+Pig-) E. gallinarum 1 * j 
E. faecium 
E. gallinarum/ E. casseliflavus E. casseliflavus (Sor- Ara+Mot+ Pig-) E. casseliflavus 2 * 
E.faecium 
E. casseliflavus E. casseliflavus E. casseliflavus (Sor- Ara+Mot+ Pig-) E. casseliflavus 1 八* 
E. casseliflavus E. gallinarum E. gallinarum (Sor-Ara+Mot+Pig-) E. gallinarum 1* 
E. avium N e g a t i v e E. raffinosus (Arg- Man+ Sor- Ara+ Raf+) E. raffinosus 2 
E. avium/ Nega t i ve E. raffinosus (Arg- Man+ Sor- Ara+ Raf+) E. raffinosus 1 
Aerococcus 
E. avium/ N e g a t i v e E. avium (Arg- Man+ Sor- Ara+ Raf-) E. avium 1 
Aerococcus 
E. durans/ Nega t i ve E. durans (Arg+ Man- Sor- Ara- Raf-) E. durans 1 
E. faecium 
Total 309 
(Ara, arabinose; Arg, arginine; Man, mannitol; Raf, raffinose; Sor, sorbitol; Mot, 
motility; Pig, pigment production; ND, not done;八’ same results for API 20 Strep and 
PCR; *, same results for PCR and conventional method) 
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The conventional tests gave the same identification results as PCR for 16 of 
these 22 isolates which yielded discrepant results by API 20 Strep and PCR. The 
remaining six isolates were found to be species other than E. faecaUs, E. /額讀， 
E. gallinarum and E. casseliflavus since no amplification products were obtained 
after PCR. Thus, PCR was chosen as the method for identification of all isolates 
from urine and bile collected in 1998 and the identity of those which were shown 
to be non-£. faecalis by PCR was confirmed by the conventional scheme. 
Among the 498 isolates collected from 1997 to 1998，403 (81%) were E. 
faecalis, 11 (15%) were E. faecium and 18 (4%) were other Enterococcus spp. 
(ei辦 of E. gallinanm, four of E. casseliflavus, three of K raffinosus, two of 五. 
durans and one of avium) (Table 6). A similar proportion of E. faecalis isolates 
were isolated from urine and bile during the two years: 86% (193 of 225) in 1997 
and 87% (149 of 172) in 1998 from urine; 46% (12 of 26) in 1997 and 67% (12 of 
18) in 1998 from bile. Similarly, the same proportion of faecium isolates were 
collected from urine during the two years, (13% (30 of 225) in 1997 and 13% (22 
of 172) in 1998). More E. faecium isolates were collected from bile collected in 
1997 than in 1998 (31% (8 of 26) and 16% (3 of 18), respectively). The number of 
enterococcal species collected from blood, body fluids and CSF was small (49 
from blood, six from body fluids and two from CSF). The majority of these 
isolates were E. faecalis (65%) while E. faecium made up 25%. 
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Table 6. Distribution of enterococcal species f rom different specimens 
P - — — 1 — — - r 
Urine Bile Blood Body fluid CSF 
O r _ s m 1997 1998 
1 川 io 19 3 2 403 (80.9) E.faecalis 193 149 12 12 32 ^ 
E. faecium 30 22 8 3 12 2 77(15.5) 
1 O 9 8(1.6) 
E. gallinarum 1 [ � ^ 
1 1 1 4 (0.8) 
E. casseliflavus i 丄 丄 
E. durans 1 1 2 (0.4) : 
• i 
E. -um 1 1 (0.2) \ 
1 
E. rqffinosus 1_ 1 \ -——^ ⑴石)_ 
I 
Sub-total 225 172 26 18 '' 





3.2. Antimicrobial susceptibilities of enterococci 
The susceptibilities of enterococci to 13 antimicrobial agents are 
summarized in Table 7. The MIC range of penicillin and ampicillin for E. faecalis 
was similar, being 0.5 or 1 mg/L _ >16 mg/L. The MIC50 and MIC90 of these two 
drugs were also similar, being 1- 2 mg/L. Only three and two (1% each) of the 404 
E. isolates tested were resistant to penicillin and ampicillin, respectively. 
However, 95% of the 76 K faecium isolates tested were resistant to penicillin and 
ampicillin. This was highly significant (p < 0.01). The MIC range of penicillin and 
ampicillin for K faecium was the same (1 - >16 mg/L) and MIC50 and MIC90 were 
both >16mg/L. 
None of the E. faecalis isolates was resistant to vancomycin (MIC range 
0.5 - 4 mg/L; MIC50 二 1 mg/L; MIC90 二 2 mg/L) and teicoplanin (MIC range 0.03 
一 0.5 mg/L; MIC50 = 0.12 mg/L; MIC90 = 0.25 mg/L). There was only one E. 
faecium isolate that was resistant to both vancomycin and teicoplanin (MIC >16 
mg/L) and one to vancomycin (MIC >16 mg/L) only. These two strains were 
isolated from urine in 1998. The MIC range of vancomycin for the vancomycin-
sensitive E. faecium was 0.5 — 4 mg/L and that of teicoplanin was 0.06 — 0.5 mg/L. 
The MIC range of gentamicin for both E. faecalis and E. faecium was 
similar, being 2 or 4 mg/L - >1024 mg/L. High-level resistance to gentamicin 
(MIC >512 mg/L) was detected in 106 (26%) E. faecalis isolates and 16 (21%) E. 
faecium isolates. Significantly more E. faecalis and E. faecium strains isolated in 
1998 (34% and 31%, respectively) were resistant to high-level gentamicin than 
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Table 7. Aiitimcrobial susceptibilities of Enterococcus species isolated from 1997 t^l998. 
Antibiotic Enterococcus spp. Year Site No. Range MIC50 MIC90 %ofR' Bp* 
Penicillin E. faecalis 1997 all 205 1 - > 1 6 2 2 2 8 
(P) 1998 all 198 1 - > 1 6 2 4 0 
1997-98 urine 342 1 - > 1 6 2 2 1 
1997-98 bile 24 1 - > 1 6 2 2 1 
1997-98 blood 32 1 - 4 2 4 0 
Total 403 1 - > 1 6 2 2 1 
E. faecium 1997 all 38 1 - > 1 6 >16 >16 95 
1998 all 39 2 - > 1 6 >16 >16 95 
1997-98 urine 52 >16 >16 >16 100 
1997-98 bile 11 1 - > 1 6 >16 >16 64 
1997-98 blood 12 >16 >16 >16 100 
Total 77 1 ->16 >16 >16 95 
Others 1997-98 all 18 0.5 - 16 1 16 11 
Total 1997-98 498 0.5 - > 1 6 2 >16 16 
Ampicillin E. faecalis 1997 all 205 0.5 - > 1 6 1 1 1 8 
(A) 1998 all 198 0.5 - > 1 6 1 2 0 
1997-98 urine 342 0.5 - > 1 6 1 2 1 
1997-98 bile 24 0.5 - > 1 6 2 2 4 
1997-98 blood 32 0.2 - 2 1 2 0 
Total 403 0.5 - > 1 6 1 2 1 
E. faecium 1997 all 38 0.5 - > 1 6 >16 >16 78 
1998 all 39 2 - > 1 6 >16 >16 95 
1997-98 urine 52 >16 >16 >16 100 
1997-98 bile 11 1 - > 1 6 >16 >16 64 
1997-98 blood 12 >16 >16 >16 100 
Total 77 1 - > 1 6 >16 >16 87 
Others 1997-98 all 18 0.5 - > 1 6 1 8 6 
Total 1997-98 498 0.5 - > 1 6 1 >16 15 
Vancomycin E. faecalis 1997 all 205 0.5 - 4 1 2 0 4 
(V) 1998 all 198 0.5 - 4 2 4 0 
1997-98 urine 342 0.5 - 4 1 2 0 
1997-98 bile 24 0.5 - 4 2 4 0 
1997-98 blood 32 1 - 4 1 2 0 
Total 403 0.5 - 4 1 2 0 
E. faecium 1997 all 38 0.5 - 4 1 2 0 
1998 all 39 0.5 - > 1 6 1 2 5 
1997-98 urine 52 0.5 - > 1 6 1 1 4 
1997-98 bile 11 0 . 5 - 1 1 1 0 
1997-98 blood 12 0 . 5 - 1 1 1 0 
Total 77 0.5 - > 1 6 1 1 3 
Others 1997-98 all 18 0.25 - 8 4 8 11 
Total 1997-98 498 0.25 - > 1 6 1 2 1 
(To be continued) 
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Table 7. Antimcrobial susceptibilities of Enterococcus species isolated from 1997 t^l998. 
Antibiotic Enterococcus spp. Year Site No. Range MIC50 MlCgp %ofR' Bp* 
Teicoplanin E. faecalis 1997 all 205 0.03 - 0 . 5 0.12 0.25 0 8 
(Tei) 1998 all 198 0.03 - 0 . 5 0.12 0.25 0 
1997-98 urine 342 0.03 - 0 . 5 0.12 0.25 0 
1997-98 bile 24 0 . 0 6 - 0 . 5 0.12 0.25 0 
1997-98 blood 32 0.06 - 0 . 5 0.12 0.5 0 
. Total 403 0.03 - 0 . 5 0.12 0.25 0 
E.faecium 1997 all 38 0.06 - 0 . 5 0.25 0.5 0 
1998 all 39 0.12 - � 1 6 0.5 0.5 3 
1997-98 urine 52 0 . 1 2 - 0 . 5 0.25 0.5 2 
1997-98 bile 11 0.06 - 0 . 5 0.25 0.5 0 
1997-98 blood 12 0 . 1 2 - 0 . 5 0.25 0.5 0 
Total 77 0 . 0 6 - > 1 6 0.5 0.5 1 
Others 1997-98 all 18 0.06 - 0 . 5 0.25 0.5 0 
Total 1997-98 498 0.03 - 3 2 0.12 0.5 0.2 
Gentamicin E. faecalis 1997 all 205 4 ->1024 32 >1024 19 512 
(G) 1998 all 198 4 ->1024 64 >1024 34 
1997-98 urine 342 4 ->1024 32 >1024 27 
1997-98 bile 24 4 - > 1 0 2 4 32 1024 26 
1997-98 blood 32 8 ->1024 128 >1024 25 
Total 403 4 - > 1 0 2 4 32 >1024 26 
E. faecium 1997 all 38 2 ->1024 8 >1024 11 
1998 all 39 4 ->1024 16 >1024 32 
1997-98 urine 52 4 - > 1 0 2 4 16 >1024 18 
1997-98 bile 11 4 - 1024 8 1024 9 
1997-98 blood 12 4 - > 1 0 2 4 16 >1024 42 
Total 77 4 ->1024 16 >1024 21 
Others 1997-98 all 18 4 - > 1 0 2 4 8 >1024 11 
Total 1997-98 498 4 ->1024 32 >1024 25 
Streptomycin E. faecalis 1997 all 205 4 ->1024 256 >1024 38 >1024 
(St) 1998 all 198 8 ->1024 256 >1024 43 
1997-98 urine 342 4 ->1024 256 >1024 33 
1997-98 bile 24 64 ->1024 1024 >1024 46 
1997-98 blood 32 32 ->1024 256 >1024 59 
Total 403 4 ->1024 256 >1024 36 
E. faecium 1997 all 38 32 ->1024 >1024 >1024 74 
1998 all 39 32 ->1024 >1024 >1024 62 
1997-98 urine 52 32 ->1024 >1024 >1024 73 
1997-98 bile II 32 ->1024 64 >1024 46 
1997-98 blood 12 128 ->102 >1024 >1024 67 
Total 77 32 ->1024 >1024 >1024 67 
Others 1997-98 all 18 32 ->1024 32 >1024 17 
Total 1997-98 498 4 ->1024 256 >1024 40 
(To be continued) 
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Table 7. Aiitimcrobial susceptibilities of Enterococcus species isolated from 1997 to 1998. 
MIC  
Antibiotic Enterococcus spp. Year Site No. Range MIC50 MIC90 %ofR' Bp* 
Chloramphenicol E.faecalis 1997 all 205 4 - 6 4 8 32 41 8 
(C) 1998 all 198 4 - 6 4 8 64 46 
1997-98 urine 342 4 - 6 4 8 32 43 
1997-98 bile 24 4 - 6 4 8 32 38 
1997-98 blood 32 4 - 6 4 8 32 44 
Total 403 4 - 6 4 8 32 44 
E. faecium 1997 all 38 0.5 - 3 2 8 16 28 
1998 all 39 1 - 32 8 32 31 
1997-98 urine 52 1 - 3 2 4 16 17 
1997-98 bile 11 0.5 - 3 2 8 8 9 
1997-98 blood 12 8 - 3 2 4 16 17 
Total 77 4 - 6 4 8 32 29 
Others 1997-98 all 18 0.25 - 8 4 32 22 
Total 1997-98 498 2 - 6 4 8 32 41 
Rifampicin E. faecalis 1997 all 205 0.25 - > 1 6 2 8 59 1 
(Rif) 1998 all 198 0.25 - > 1 6 2 8 55 
1997-98 urine 342 0.25 - > 1 6 2 8 57 
1997-98 bile 24 0.25 - 8 1 4 50 
1997-98 blood 32 1 - � 1 6 4 8 59 
Total 403 0.25 - > 1 6 2 8 56 
E. faecium 1997 all 38 0.5 - > 1 6 8 >16 86 
1998 all 39 1 - > 1 6 >16 >16 97 
1997-98 urine 52 1 - > 1 6 8 >16 96 
1997-98 bile 11 0.5 - > 1 6 8 >16 91 
1997-98 blood 12 8 - > 1 6 8 >16 100 
Total 77 0.5 - > 1 6 8 >16 92 
Others 1997-98 all 18 0.25 - 8 1 8 28 
Total 1997-98 498 0.25 - 32 2 16 61 • 
Sparfloxacin E. faecalis 1997 all 205 0.12 - 6 4 0.5 1 7 1 
(Spx) 1998 all 198 0.12 - 128 0.5 1 9 
1997-98 urine 342 0.12 - 6 4 0.5 1 7 
1997-98 bile 24 0.12 - 8 0.5 1 8 
1997-98 blood 32 0.12 - 128 0.5 128 19 
Total 403 0.12 - 128 0.5 1 8 
E. faecium 1997 all 38 0 . 1 2 - 6 4 8 64 69 
1998 all 39 0.12 -128 32 128 76 
1997-98 urine 52 0.12-128 8 64 88 
1997-98 bile 11 0.25 - 6 4 1 64 46 
1997-98 blood 12 0.5 - 128 64 128 75 
Total 77 0.12 - 128 16 128 80 
Others 1997-98 all 18 0.12 -16 0.5 1 6 
Total 1997-98 498 0.12 - 128 0.5 16 19 
(To be continued) 
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Table 7 Antimcrobial susceptibilities of Enterococcus species isolated from 1997 to 1998. 
MIC  
Antibiotic Enterococcus spp. Year Site No. Range MIC50 MIC90 %ofR' Bp* 
Quinupristin/ E. faecalis 1997 all 205 0.5 - 8 4 4 96 1 
Dalfopristin 1998 all 198 0 .12-16 4 8 93 
(Str) 1997-98 urine 342 0.25 - 8 4 8 96 
1997-98 bile 24 0.5 - 8 4 4 88 
1997-98 blood 32 0 . 1 2 - 8 4 8 84 
Total 403 0.5 - 16 4 8 95 
E. faecium 1997 all 38 0.25 - 4 0.5 4 5 
1998 all 39 0 .06 - 8 0.5 2 13 
1997-98 urine 52 0.06 - 8 0.5 1 10 
1997-98 bile 11 0 . 1 2 - 2 0.5 1 9 
1997-98 blood 12 0.06 - 0 . 5 0.12 0.5 0 
Total 77 0.06 - 8 0.5 1 9 
Others 1997-98 all 18 0 . 1 2 - 4 1 2 44 
Total 1997-98 498 0 .06 - 16 4 8 80 
*BP = breakpoint 
R = resistance 
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those isolated in 1997 (19% and 11%, respectively) (p <0.01). Significantly more 
E. faecium (67%) isolates were resistant to high-level streptomycin (MIC >1024 
mgfL) Wim E. faecalis (36%) (p < 0.01). The MIC range of streptomycin for E. 
faecium was 32 - >1024 mg/L and the MIC50 and MIC90 were both >1024 mg/L, 
while those for E. faecalis was 4 ->1024 mg/L, 256 mg/L and >1024 mg/L, 
respectively. Significantly more E. faecium isolates from urine (18%) were 
resistant than those from bile (9%) (p <0.01). 
Significantly more E. faecium (92%) isolates were resistant to rifampicin 
than E. faecalis (56%) (p<0.01). Consequently, the MIC range of rifampicin for E. 
faecalis was 0.25 - >16 mg/L and MIC50 and MIC90 were 2 mg/L and 8 mg/L, 
respectively, while those for E. faecium were 0.5 - >16 mg/L, 8 mg/L and >16 
mg/L, respectively. More than 50% of E. faecium isolates were resistant to 
trimethoprim and co-trimoxazole (53% and 58%, respectively) while less than 20% 
of E. faecalis isolates were resistant (16% and 15%, respectively). 
In contrast, significantly more E. faecalis was resistant to chloramphenicol 
than E. faecium (44% and 29%, respectively) (p < 0.01). More than 90% of the E. 
faecalis and E. faecium isolates were resistant to erythromycin. The MIC range of 
sparfloxacin (RJP 64206) for both E. faecalis and E. faecium was similar, being 
from 0.12 mg/L to 128 mg/L. However, the MIC50 and MIC90 for E. faecalis were 
0.5 mg/L and I mg/L. respectively, while for E. faecium�they were 16 mg/L and 
128 mg/L, respectively. Significantly more E. faecium isolates were resistant to 
sparfloxacin than E. faecalis (66% and 8%, respectively; p < 0.01). More E. 
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faecium isolates from urine (88%) were resistant than those from bile (46%) (p 
<0.01). 
The MICs of quinupristin/dalfopristin (RP 59500) for E. faecalis ranged 
from 0.5 mg/L to 16 mg/L and those for E. faecium ranged from 0.06 mg/L to 8 
mg/L. The MIC50 and MIC90 for E. faecalis were 4 mg/L and 8 mg/L, respectively, 
E. faecium, they were 0.5 mg/L and 1 mg/L, respectively. Consequently, 
significantly more E. faecalis isolates were resistant to this combination of drugs 
than E. faecium (17% and 1 %, respectively; p < 0.01). 
Only two {E. durans and E. raffinosus) of the 18 other enterococcal species 
were resistant to penicillin or ampicillin. High-level gentamicin resistance was 
seen in two isolates (both were E. gallinarum). High-level streptomycin was seen 
in four isolates {E. gallinarum (3) and E. durans (1)). Only two isolates {E. 
gallinarum and E. casseliflavus) were resistant to vancomycin (MIC = 8 mg/L) and 
none of them was resistant to teicoplanin. More than 80% were resistant to 
erythromycin, more than 20% To chloramphenicol and rifampicin and 17% to 
trimethoprim and co-trimoxazole. Less than 10% were resistant to sparfloxacin and 
none of them were resistant to quinupristin/dalfopristin (RP 59500). 
3.3. Detection of vancomycin resistance genes in enterococci by PCR 
Isolates with vancomycin MICs > 4 mg/L were tested for the presence of 
vancomycin resistance genes by PCR. A total of 47 isolates were tested {E. faecalis 
(35), E. faecium (2), E. gallinarum (8) and E. casseliflavus (2)). They were 
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subjected to PCR analysis with primers specific to vcmli vcni('-I and van( 
2 C-3 genes (section 2.6.1). Twelve isolates were found to have van genes (Table 8 
and Figure 2). The vcwA gene was detected in one E. faecium isolate resistant to 
both vancomycin (MIC >16 mg/L) and teicoplanin (MIC >16 mg/L). The vanH 
gene was detected in another E. faecium isolate that was resistant to vancomycin 
(MIC >16 mg/L) but sensitive to teicoplanin (MIC = 0.5 mg/L). The vanC-1 gene 
was detected in eight E. gallinarum isolates and vanC-2 gene was detected in two 
E. casseliflavus isolates. No amplification products were detected in the remaining 
35 isolates (all vancomycin MIC = 4 mg/L). 
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Table 8. Presence of van A, vanB, vanC-1 and vanC-2 genes in enterococci with 
vancomycin MIC > 4 mg/L. 
MIC (mg/L) 
Enterococcus spp. Van genotype Vancomycin Teicoplanin No of isolates 
E. faecium vanA >16 >16 1 
E. faecium vanB >16 0.5 1 
E. gallinarum vanC-1 4 - 8 0.06 - 0.5 8 
E. casseliflavus vanC-2 4 - 8 0.06 - 0.25 2 
E. faecalis | Nil | 4 0.06 - 0.5 35 
Total 47 
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Figure 2. Agarose gel electrophoresis pattern of amplified products after PCR of 
enterococci with vancomycin MIC > 4mg/L using primers specific for 
van genes. 
M 1 2 3 4 5 6 7 8 9 M 
Size marker ((|)X174 — Haelll digest) in Lane M. Reagent control in Lane 1. Test 
isolates were contained in lanes 2 -5. Lane 2: isolate with vanC-1 gene, Lane 3: 
isolate with vanB gene, Lane 4: isolate without van gene, Lane 5: isolate with vanA 
gene. Amplified products from control strains in lanes 6 - 9 . Lane 6: E. 
casseliflavus (ATCC 25788) with vanC-2 gene. Lane 7: E. gallinarum (ArB39) 
with vanC-\ gene. Lane 8: E. faecalis (ATCC 51922) with vanB gene, Lane 9: E. 
faecium (AIB40) with vanA gene. 
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3.4. Detection of gene coding for aminoglycoside-modifying enzyme (AAC6'-
APH2") by PCR 
One hundred and twenty-four isolates (106 of E. faecalis, 16 of 五.faecium 
and 2 of E. gallinarum) with high-level resistance to gentamicin (MIC >1024 
mg/L) were selected for detection of the presence of aac(6')-aph(2") gene. They 
were subjected to PCR analysis using primers specific to 16S rRNA gene and 
aac(6')-aph(2") gene. All generated the expected amplification product with 
primers of 16S rRNA gene. One hundred and twenty isolates (102 E. faecalis, 16 
E. faecium and 2 E. gallinarum) generated the expected amplification products 
with primers specific for aac(6')-aph(2"). Four E. faecalis isolates as well as 20 
randomly selected isolates with gentamicin MICs <256 mg/L gave no 
amplification products (Table 9, Figure 3). Thus, these isolates probably harbour 
genes other than aac(6')-aph(2") or did not harbour any aminoglycoside resistance 
genes. 
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Table 9. Characteristics of enterococci with gentamicin MIC range = 4 - >1024 
mg/L. 
PCR product using primers for 
Enterococcus spp. Gentamicin MIC (mg/L) 16SrRNA aac(6')-aph(2") No. of isolates 
E. faecalis >1024 + + 56 
+ - 3 
1024 + + 46 
+ - 1 
4 -256 + - 14 ： 
E. faecium > 1024 + + 9 
1024 + + 7 
4 - 1 6 + - 4 
E. gallinarum >1024 + + 2 '； 
8 + - 1 
E. raffinosus 8 + - 1 | 
Total 144 ) 
. 1 i : 
+ = PCR product present 
- = N o PCR product 
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Figure 3. Agarose gel electrophoresis pattern of amplified products obtained by 
PCR using primers specific for 16S rRNA and aac(6')-aph(2") genes. 
M 1 2 3 4 5 6 M 
16SrRNA PCR product of 
Size marker ((|)X174 — HaellY) digest in Lane M. Amplified products from control 
strains in lane 1: S. aureus (ATCC 29213) and lane 2: S. aureus (77040101). 
Reagent control in Lane 3. Tested isolated were contained in lanes 4 - 6 . Lane 4 -
6: presence of aac(6')-aph(2") gene. 
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3.5. Detection of p-lactamase in enterococci 
Seventy-six isolates (72 of E. faecium, three of E. faecalis and one of E. 
durans) with ampicillin MIC >8 mg/L were tested for the production of (3-
lactamase using cefinase disc. P-Lactamase was not detected in all the isolates 
tested. 
3.6. Resistance pattern of enterococci 
Isolates were regarded as resistant to an antibiotic if the MIC was greater 
than the concentration of that antibiotic for susceptible strains according to the 
recommendation of the NCCLS (1999). Only two isolates were susceptible to all 
the antibiotics tested while the rest were resistant to one to 10 antibiotics in a total 
of 88 patterns (Table 10). About 40% of the isolates were resistant to one to three 
antibiotics and 17% were resistant to more than seven antibiotics. There were 20 
isolates that were resistant to nine antibiotics with the resistance pattern A P G St E 
Tm Sxt C Rif Spx being found in 19 (18 E. faecium, 1 E. faecalis) of them. The 
most common resistance pattern was E Rif Str being found in 14% of isolates (67 
of E. faecalis and one other enterococcal species), followed by E Str (12%, 56 of 
E. faecalis and 2 other enterococcal species), E C Rif Str (6%, 31 of 五.faecalis and 
one other enterococcal species) and St E C Rif Str (5%, 27 of E. faecalis). The 
other resistance patterns (except A P G St E Tm Sxt C Rif Spx) were each found in 
1 - 17 (0 .2-3%) isolates. 
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Table 10. Antibiotic resistance phenotypes of the 498 enterococcal isolates. 
No. of antibiotic Resistance pattern No. of strains Total 
resistance E. faecalis E. faecium Others (%) 
0 - - 2 2 (0.4) 
1 E 5 i 4 f o ~ 
Str 3 - - 3 
T o ^ 13 (2.6) 
2 E ^ ^ - 2 ^ 
ERif 5 2 1 8 
RifStr 2 1 - 3 
VE 1 1 
T ^ 70 (14) 
3 ERifStr ^ - i ^ 
EC Str 17 - - 17 
St E Str 13 - - 13 
GEStr 8 - - 8 
C RifStr 2 - - 2 
P E Str - - 1 1 
ECRif 1 - - 1 
E Tm Sxt 1 - - 1 
VERif - - 1 1 
T o ^ 112(22) 
4 EC RifStr - 1 ^ 
St ERif Str 17 - - 17 
St EC Str 11 - - 11 
G ERif Str 8 - - 8 
E Tm Sxt Str 6 - 1 7 
G E C Str 7 - - 7 
G St E Str 5 - - 5 
St ECRif 3 - - 3 
StESpxStr 3 - - 3 
ERifSpx Str 2 - - 2 
APERif - 1 - 1 
E Tm Sxt C 1 - - 1 
G E Spx Str 1 - - 1 
G E Tm Sxt 1 - - 1 
G R i f S p x Str 1 - - 1 
To^ 100 (20) 
- :Ni l (To be continued) 
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Table 10. Antibiotic resistance phenotypes of the 498 enterococcal isolates. 
No. of antibiotic Resistance pattern No. of strains Total 
resistance E. faecalis E. faecium Others  
5 StECRifStr ^ - - 27 
GECRifStr 10 10 
G E Tm Sxt Str 5 5 
GStERifStr 4 4 
E Tm Sxt C Str 3 3 
G St E C Str 3 - - 3 
APERifSpx - 2 - 2 
G St E Spx Str 2 - - 2 
ETm SxtRifStr 2 2 
APCRifSpx - 1 - 1 
A P St E C - - 1 1 
G E R i f S p x Str 1 1 
St E C Spx Str 1 1 
St E Tm Sxt Rif 1 1 
St E T m Sxt Spx 1 1 
St E Tm Sxt Str 1 1 
St E Rif Spx Str 1 1 
T o ^ 66 (13) 
6 G St E C Rif Str 16 - - 16 
A P St E Rif Spx - 12 - 12 
St E Tm Sxt C Str 5 5 
G St E C Spx Str 4 - - 4 
AP GERifSpx - 3 - 3 
GETm SxtRifStr 3 3 
G E Tm Sxt C Str 2 - - 2 
A P V E Tm Sxt - 1 - 1 
E Tm Sxt C Spx Str 1 1 
E Tm Sxt C Spx Str 1 1 
G E Tm Sxt Spx Str 1 1 
G St E T m Sxt Str 1 1 
St E T m SxtRifStr 1 1 
T o ^ 51 (10) 
-:Nil (To be continued) 
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Table 10. Antibiotic resistance phenotypes of the 498 enterococcal isolates. 
No. of antibiotic Resistance pattern No. of strains Total 
resistance E. faecalis E. faecium Others  
7 G St E Tm Sxt C Str 6 - 1 7 
A P E T m S x t R i f S p x - 4 - 4 
A P St E Tm Sxt Rif - 4 - 4 
G E T m S x t C R i f S t r 3 3 
G S t E C R i f S p x Str 3 3 
S t E T m S x t C R i f S t r 3 - - 3 
A P G St E C Rif - 1 - 1 
A P G E Tm Sxt Rif - 1 - 1 
A P G E R i f S p x Str - 1 - 1 
A P S t E R i f S p x Str - 1 - 1 
AP StTm SxtRifSpx - 1 - 1 | 
G E Tm Sxt C Spx Str 1 1 ；! 
G St E Tm Sxt Spx Str 1 1 
PG St EC Spx Str 1 - - 1 
St E Tm Sxt C Spx Str 1 - - 1 j  
T o ^ 33 (6.6) 丨 
8 A P St E T m SxtRi fSpx - 9 - 9 ] 
G St E Tm Sxt C Spx Str 5 1 6 j 
AP GETm SxtRifSpx - 4 - 4 j 
G St ETm SxtCRifStr 3 3 J 
A P St E Tm Sxt C Rif - 2 - 2 ；! 
A P G E C R i f S p x Str - 1 - I ) 
A P G E Tm Sxt C Rif - 1 - 1 
A P G St E Tm Sxt Spx - 1 - 1 :: 
A P V T e i G E R i f S p x - 1 - 1  
Total 28 (5.6) 
9 A P St E T m Sxt C Rif Spx 1 18 - 19 
A P G S t E T m SxtRifSpx - 1 - 1 
T o ^ 20 (4) 
10 A P St E Tm Sxt C Rif Spx Str 1 1 - 2 
A P G S t E T m Sxt C Rif Spx - 1 - 1 
T ^ 3 (0.6) 
Total 498 (100) 
- :Ni l 
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3.7. Multi-resistant enterococci investigated by pulsed-field gel electrophoresis 
Isolates that satisfied the following criteria were selected for molecular 
typing by pulsed-field gel electrophoresis: 
I. Resistant to the breakpoint concentration of an antibiotic for resistant 
Strains recommended by the NCCLS (i.e. penicillin [P] >8 mg/L, ampicillin 
A] >8 mg/L, vancomycin [V] >8 mg/L, teicoplanin [Tei] >8 mg/L, 
gentamicin [G] >512 mg/L, streptomycin [St] >1024 mg/L, erythromycin 
[E] >4 mg/L, trimethoprim [Tm] >8 mg/L, cotrimoxazole [Sxt] >32 mg/L, 
chloramphenicol [C] >16 mg/L, rifampicin [Rif] >2 mg/L, sparfloxacin 
[Spx] >2 mg/L and quinupristin/dalfopristin (RP 59500) [Str] >2 mg/L); 
II. Simultaneously resistant to eight or more antibiotics; and 
III. With the most common resistance phenotypes. 
According to the above criteria, 50 isolates (42 E. faecium isolates and 8 E. 
faecalis isolates) were selected. Based on their resistance phenotypes, the E. 
faecium isolates could be divided into four groups according to their resistance to 
ampicillin/ gentamicin and/or streptomycin (high concentration) in addition to 
various other antibiotics (Table 11). Group I consisted of three isolates with 
ampicillin resistance and high-level gentamicin and streptomycin resistance, group 
II consisted of six isolates with ampicillin and high-level gentamicin resistance, 
group n i consisted of 32 isolates with ampicillin and high-level streptomycin 
resistance and group IV consisted of two isolates with ampicillin resistance. 
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Table 11. Distribution q^E. faecium by resistance patterns. 
Group Resistance pattern No. of isolates 
l a APGStETmSxt RifSpx ^ 2 
b APGStETmSxt Spx 1 
II a APGETmSxt RifSpx 3 
b A P G E Tm Sxt C Rif 1 
c A P G E C RifSpx Str 1 
d A PVTeiGE RifSpx 1 
m a A P St ETm Sxt RifSpx 19 
b APStETm SxtRif 8 
c APStETmSxtCRifSpx 3 
d APStETm SxtCRif 1 
IV APETm Sxt RifSpx ^  




By PFGE, the 42 E. faecium isolates could be typed into a total of 37 PFGE 
types (types 1 - 37). All except five types consisted of one isolate each. These five 
types were 1, 4, 7, 19 and 21 and each consisted of two isolates. Twenty-one types 
were of >90% similarity and could be grouped into eight groups (groups A to H) 
(Figure. 4). Group A consisted of four types, groups C, E^and F consisted of three 
types each and groups B, D, G and H consisted of two types each. 
Table 12 shows the relationship between resistance patterns and PFGE 
types of E. faecium. Resistance pattern III a was the most common, being exhibited 
by 45% (19) of isolates. Among these isolates, 14 could be grouped into five 
different PFGE group (A, B, C, E, H) while the remaining isolates were of <90% 
similarity. The next most common resistance pattern was III b exhibited by 19% 
(8) of isolates. Three isolates belonged to the same PFGE group (F), one belonged 
to group C and the rest belonged to four types of <90% similarity. Isolates of the 
same resistance pattern could be of different PFGE types or groups while strains 
with the same PFGE types or groups could be resistant to different spectra of 
t 
antibiotics. » 
The eight E. faecalis isolates selected for PFGE could be divided into three 
groups (groups I - III) according to their resistance pattern. All were resistant to 
high-level gentamicin and streptomycin except one that was resistant to 
streptomycin and ampicillin but not gentamicin (Table 13). Group I (G St E Tm 
Sxt C Spx Str) consisted of four isolates and group II (G St E Tm Sxt C Rif Str) 
4 
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By PFGE, the 42 E.faecium isolates could be typed into a total of 37 PFGE 
types (types 1 - 37). All except five types consisted of one isolate each. These five 
types were 1, 4, 7, 19 and 21 and each consisted of two isolates. Twenty-one types 
were of >90% similarity and could be grouped into eight groups (groups A to H) 
(Figure. 4). Group A consisted of four types，groups C, E and F consisted of three 
types each and groups B, D, G and H consisted of two types each. 
Table 12 shows the relationship between resistance patterns and PFGE 
types oi E.faecium. Resistance pattern III a was the most common, being exhibited 
by 45% (19) of isolates. Among these isolates, 14 could be grouped into five 
different PFGE group (A, B, C, E, H) while the remaining isolates were of <90% 
similarity. The next most common resistance pattern was III b exhibited by 19% 
(8) of isolates. Three isolates belonged to the same PFGE group (F), one belonged 
to group C and the rest belonged to four types of <90% similarity. Isolates of the 
same resistance pattern could be of different PFGE types or groups while strains 
with the same PFGE types or groups could be resistant to different spectra of 
antibiotics. 
The eight E. faecalis isolates selected for PFGE could be divided into three 
groups (groups I - III) according to their resistance pattern. All were resistant to 
high-level gentamicin and streptomycin except one that was resistant to 
streptomycin and ampicillin but not gentamicin (Table 13). Group I (G St E Tm 
Sxt C Spx Str) consisted of four isolates and group II (G St E Tm Sxt C Rif Str) 
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consisted of three isolates. Group III (A P St E Tm Sxt Rif Spx) consisted of only 
one isolate. These E. faecalis isolates could be typed into a total of seven PFGE 
types and only two (types 4 and 5) were of >90% similarity (Figure 5). Two 
isolates were of the same PFGE type (type 1). Table 14 shows the relationship 
between resistance patterns and PFGE types of E. faecalis. Isolates of the same 
resistance patterns belonged to different PFGE types, a finding similar to that of E. 
faecium. 
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Figure 4. Dendrogram showing relationships between the 42 multi-resistant E. 
faecium based on their PFGE patterns of ^Sm^zl-digested genomic DNA. 
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Table 12. Correlation of resistance patterns and PFGE types o^E. faecium. 
PFGE Resistance pattern 
Group Type l a l b II a l i b l i e II d III a III b III c III d IV Total 
~ A i i “ i 2 
2 1 1 
3 1 1 
4 1 1 2 
""“B 5 1 1 
6 1 1 
C 7 2 2 
8 1 1 
9 1 L _ 
~~ id 16 r ~ 1 
n 1 1 
~~~E 19 2 2 
20 1 1 
^ 2 2 
~ F ^ i i ~ 
23 1 1 
^ 1 1 
G 2 8 i “ i ~ 
29 1 1 
H 33 i 1 
34 1 1 
“ - i 1 
11 1 1 
12 1 1 
13 1 1 
14 1 1 
15 1 1 
18 1 1 1 
25 1 1 
26 1 1 
27 1 1 
30 1 1 
31 1 1 
32 1 1 
35 1 1 
36 1 1 
^ 1 1 
Total 2 i 3 1 2 1 1 9 8 3 1 4 2 ~ 
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Table 13. Distribution of multi-resistant E. faecalis by resistance patterns. 
Group Resistant phenotype No. of strains 
I G St E Tm Sxt C Spx Str 1 
G St E Tm Sxt C Spx Str 2 
G St E Tm Sxt C Spx Str 1 
II G St E T m SxtCRif Str 1 
G St E T m SxtCRif Str 1 
G St E T m SxtCRif Str 1 
III A P S t E T m Sxt RifSpx 1 
Total 8 
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Figure 5. Dendrogram showing relationships between the eight multi-resistant E. faecalis 
isolates based on their PFGE patterns of *Sm<3l-digested genomic DNA. 
Percentage similarity 
Type Group 
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Table 14.-Correlation of resistance pattern and PFGE types oiE. faecalis. 
PFGE Resistance pattern 
Group Type I H m Total 
A 4 1 1 
5 1 1 
- 1 1 1 
2 2 2 
3 1 1 
6 1 1 
7 1 1 
Total 4 3 1 8 
76 
4. Discussion 
During the past twenty years, enterococci have emerged as important 
pathogens because of their association with nosocomial infections. They are 
increasingly being isolated from hospitalized patients with urinary tract infections, 
bacteraemia and wound infections (Murray, 1990; Schaberg, Culver & Gaynes, 
1991). Besides being intrinsically resistant to various antibiotics, they also 
acquired resistance to many antibiotics. With the acquisition of glycopeptide 
resistance genes from other bacterial species, vancomycin-resistant enterococci 
(VRE) have developed and become widespread in many places. Workers in 
Europe showed that glycopeptide-resistant enterococci have been isolated from 
both animal and human faeces (Gordts et al, 1995; Welton et al, 1998; Phillips, 
1999). In contrast, such strains were mainly isolated from hospitalized patients in 
the United States (Murray, 1997). This was probably due to the widespread use of 
avoparcin, a glycopeptide used as a growth promotor, in animals in Europe while 
the drug was banned for animal use in 1997 in the United States. It could be 
speculated that the prevalence of VRE infection in the United States was due to 
extensive use of glycopeptides in humans while in Europe, it was due to the 
increased use of this group of antibiotics in both humans and animals (French, 
1998; Phillips, 1999). Thus, the only strategy against these organisms is to prevent 
their spread by strict infection control measures (Spera & Farber, 1992; Murray, 
1995; Heath, Blackmore & Gordon, 1996; Leclercq, 1996). 
The situation of enterococcal infections and their antibiotic resistance in 
Hong Kong is largely unknown. We therefore set out to determine the distribution 
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of enterococci and their antibiotic susceptibilities in a large general hospital in 
Hong Kong. It is hoped that results of this study would elucidate the types and 
levels of antibiotic resistance of enterococcal infections in Hong Kong. Clinicians 
could therefore be guided for the best choice of antimicrobial agents in treating 
their patients with enterococcal infections. Indeed, we have revealed that antibiotic 
resistance among our enterococcal strains was high. This would be discussed 
further in the section on antibiotic susceptibilities of enterococci. 
Enterococci isolated from urine, bile, blood, body fluids and CSF were 
selected for the study. This is because urinary tract infection is the most common 
infection caused by enterococci (Murray, 1990) while serious infections such as 
endocarditis, septicaemia, meningitis, etc can also be caused by enterococci. Since 
more than a thousand enterococcal isolates were isolated from urine and bile every 
year, we could only manage to test a limited but reasonable number of isolates 
/ 
from these specimens. By testing isolates collected during the same period (April 
to June) in two consecutive years, we might be able to detect changes, if any, in the 
prevalence of antibiotic resistance. In contrast, many fewer isolates were from 
blood, body fluid and CSF so that isolates from these specimens collected 
throughout a year were studied (April, 1997 to March, 1998). Isolates from wound 
specimens were excluded from the study because their clinical significance is 
questionable (Low, Willey & McGeer, 1995; Facklam & Sahm, 1995). 
This study showed that the majority of enterococci were isolated from urine 
(80%) even though organisms isolated from this type of specimen were collected 
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only during a six-month study period while organisms from blood which made up 
10% of the isolates studied were collected over 12 months. Organisms from bile, 
body fluids and CSF made up the remaining 10% of the isolates collected. Thus, 
urinary tract infection was the most common infection caused by enterococci. 
Besides, more isolates were collected from urine and bile in 1997 than in 1998. 
Whether this was due to a decrease in the number of enterococcal infections or an 
overall decrease in the number of infections in 1998 had to be evaluated by 
analyzing the total number of all infections in this year. 
The distribution of enterococci in different specimens was similar to that of 
other studies. In their study in the United States, Gordon et al (1992) found that the 
majority of isolates are isolated from the urinary tract (57%) followed by non-
surgical wound (13.3%), blood (10.5%), surgical wound (8.8%) and miscellaneous 
sites (10.4%). McNamara and colleagues (1995) also found that the majority of 
their strains are isolated from the urinary tract (66%) with those from wound and 
soft tissue (23%) being next in prevalence and only 3% are isolated from blood. 
More than 80% of the enterococci studied were E. faecalis (81%) while E. 
faecium made up only 15%. The other Enterococcus species were rarely isolated 
(4%). This distribution of enterococcal species was also similar to that found in 
other studies. In the series of Gordon et al (1992) and Vandamme et al (1996), the 
respective figures are 90%, 8-9% and 2%. In contrast, in Greece during 1993-1994, 
Douboyas & Tsakris (1995) found that of their 224 isolates, only 48% were E. 
faecalis while E. faecium made up 29%. Although almost 70% of the isolates 
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reported by Perlada and colleagues (1997) were identified as E. faecalis (69%), E. 
faecium constituted (29%) of their collection of enterococci. The distribution of 
species thus varies in different countries. This further supports the fact that we 
should study the distribution of enterococcal species to reflect the local situation. 
Conventional biochemical method is the "gold standard" used in the 
identification of enterococci. Commercially available biochemical kits such as API 
20 Strep and API 32 Strep are now widely used despite of their high price because 
they are easy and simple to use. Recently, molecular methods such as PCR that is 
more rapid have been used in the identification of enterococci. Four clinically-
important enterococcal species E. faecalis, E. faecium, E. gallinarum and E. 
casseliflavus can be definitively identified using specific primers in PCRs (Dutka-
Malen, Evers & Courvalin, 1995; Free & Sahm, 1996). Since our laboratory 
mainly used API 20 Strep to identify enterococci to species level, we investigated 
the possibility of using PCR as an alternative method. Similar to findings of other 
workers (Nachamkin, Lynch & Dalton，1982; Jorgensen, Crawford & Alexander, 
1983; Facklam, Rhoden & Smith，1984; Facklam et al, 1985; You & Facklam， 
1986; Ruoff et al, 1990; Teixeria et al, 1995; Donabedian et al, 1995), we found 
that enterococcal species other than E. faecalis could not be accurately identified 
by API 20 Strep: only three out of the 243 isolates (1%) of E. faecalis but seven of 
52 isolates (13%) of E. faecium and 12 (86%) of 14 isolates of other enterococcal 
species were misidentified. Conventional biochemical tests had to be carried out to 
give a definitive identification of these organisms. Recently, the use of API has 
been evaluated against BBL crystal systems for the identification of VRE. API 20 
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Strep could only correctly identify 57% of E. faecium while the Crystal Gram 
Positive and Rapid Gram Positive kits could correctly identify 93% and 96%, 
respectively of the strains (Hamilton-Miller & Shah, 1999). Although BBL crystal 
systems appeared to be superior to API 20 Strep in identifying enterococci, they 
are not available in Hong Kong. 
Both PCR and conventional biochemical tests gave the same identification 
results for 63 of the 69 non-E. faecalis isolates identified by API 20 Strep. These 
included 52 E. /a^c/wm isolates, five E. gallinarum isolates, three isolates of each 
E. casseliflavus and E. faecium. Six isolates failed to give any amplification 
product since only primers specific for the gene coding for D-alanine:D-alanine 
ligases in E. faecalis or E. faecium (ddk. faecalis and CMIE. faecmm) and vanC-1 or 
vanC-2/C-3 genes of E. gallinarum or E. casseliflavus/E. flavescens, respectively, 
were used. Isolates that were not these enterococcal species had to be identified by 
supplementary tests such as hydrolysis of arginine, fermentation of mannitol, 
sorbitol, arabinose and raffinose, motility and pigment production (Facklam & 
Collin, 1989). Thus, PCR could only correctly identify E. faecalis, E. faecium, E. 
gallinarum and E. casseliflavus while for other species, specific primers had to be 
designed (Dutka-Malen, Evers & Courvalin, 1995; Arthur, Reynolds & Courvalin， 
1996; Free & Sahm, 1996; Clark etal, 1998). 
The vanC-1 and vanC-2/C-3 genes are present intrinsically in E. gallinarum 
and E. casseliflavus/E. flavescens, respectively, that is, they are chromosomally-
mediated and are not easily transferred to other species (Toye et al, 1997; Clark et 
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al, 1998). However, the possibility of transfer of these genes by transformation to 
other bacterial organism cannot be excluded. Therefore，supplementary tests 
(motility and pigment formation) should be performed to confirm the identity oiE. 
gallinarum and E. casseliflavus!E. flavescens when they were identified as such by 
PCR. 
Although PCR could correctly identify clinically important enterococci, 
namely E. faecalis and E. faecium, this method might not be suitable for use in a 
routine Microbiology laboratory. Firstly, special techniques and equipment were 
required. Secondly, it would not be cost-effective if too few isolates were tested at 
one time. However, it could be used under certain circumstances especially when 
presence of vancomycin-resistant enterococci (VRE), high-level gentamicin-
resistant or P-lactamase-producing enterococci were suspected. As PCR could 
provide a definitive identification within a few hours, it would be very useful for 
infection control purposes as health care personnel could be alerted to take prompt 
action to prevent the spread of the organism. 
E. faecium was found to be more antibiotic resistant than E. faecalis as 
noted in other localities (McNamara, King & Symth; 1995; Perlada, Smulian & 
Cushion, 1997; Huycke, Sahm & Gilmore，1998). They are also more resistant to 
penicillin, ampicillin, streptomycin, trimethoprim, rifampicin and ciprofloxacin 
than other enterococcal species (Gordon et al, 1992; Vandamme et al) 1996; 
Tsakris, Pournarsa & Douboyas, 1997; Reinert et al, 1999; Andrews et al, 2000). 
In this study, a large proportion of E. faecium isolates was resistant to penicillin 
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and ampicillin (65%), streptomycin (45%), trimethoprim (34%), rifampicin (60%) 
and ciprofloxacin (10%). In contrast, the corresponding figures for E. faecalis were 
5%, 20%，15%, 30% and 5%. 
Although VRE remain a major problem in hospitals world-wide (Kaplan, 
Gilligan & Facklam，1988; Murray, 1995; Shay et al, 1995; Murray, 1997; Noskin, 
1997)，we only detected 12 VRE isolates from the Prince of Wales Hospital in 
1998. This was the first batch of VRE found in Hong Kong. Two of these were E. 
faecium, one phenotypically VanA (resistant to both vancomycin and teicoplanin) 
and the other phenotypically VanB (resistant to vancomycin but susceptible to 
teicoplanin). The other 10 isolates were E. gallinarum (8) and E. casseliflavus (2)， 
exhibiting low-level vancomycin resistance (MIC of vancomycin 4 - 8 mg/L) of 
VanC phenotype. Only a few other places such as in Ireland, Greece and Germany 
where a low prevalence of VRE was reported. This may be due to the limited use 
of vancomycin, avoparcin and other broad-spectrum such as cephalosoprins, and 
stringent infection control procedures (McNamara, King & Symth, 1995; 
Vandamme et al, 1996; Tsakris, Pournaras & Douboyas, 1997; French, 1998; 
Reinert et al, 1999). The very small number of VRE isolated in our hospital might 
probably be due to the fact that our hospital had an efficient infection control team 
that was responsible for preventing the spread of infections within the hospital. In 
addition, the use of avoparcin as a growth promoter for food animals might not be 
widespread in Hong Kong. 
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A similar proportion of E. faecalis and E. faecium were resistant to high-
levels of gentamicin (26% and 21%, respectively) but the percentage of 
gentamicin-resistance enterococci isolated in 1998 was higher than in 1997, 
namely E. faecalis (34% in 1998 vs 19% in 1997) and E. faecium (32% in 1998 
and 11% in 1997). Significantly more E. faecium were resistant to streptomycin 
than E. faecalis (71% versus 43%). A much smaller proportion of the other 
enterococcal species were resistant to high-level gentamicin and streptomycin 
(11% and 22%, respectively). These figures were similar to those reported in Irish, 
Greek and German hospitals (McNamara，King & Smyth，1995; Tsakris, Pournaras 
& Douboyas, 1997; Reinert et al, 1999). 
Most of the enterococci isolates were resistant to nalidixic acid and the 
fluoroquinolones (Greenwood, 1989). However, the more recently developed 
fluoroquinolones exhibited a moderate degree of activity. Sparfloxacin belonged to 
the third generation fluoroquinolones which has been shown to have a better 
activity against gram-positive organisms (Qadri, 1992). Since NCCLS did not 
recommend a breakpoint concentration for sparfloxacin, we chose 1 mg/L, a value 
which is the same as that for ciprofloxacin. Although 19% of enterococci were 
resistant to sparfloxacin, most of the resistant strains were E. faecium, and more 
than 90% of E. faecalis and other enterococcal species were susceptible. In the 
study of Qadri (1992), sparfloxacin showed excellent activity against enterococci 
with 92% of all the 59 isolates being susceptible to sparfloxacin at 4 mg/L, while 
only 22% and 27% are susceptible to norfloxacin and ciprofloxacin, respectively. 
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Quinupristin/dalfopristin (RP 59500) is the combination of two new 
semisynthetic water-soluble streptogramins with good activity against enterococci 
other than E. faecalis (Cormican & Jones, 1996; Finch, 1996; Witte，Wirth & 
Klare, 1999). It is also active against most glycopeptide resistant strains of E. 
faecium (Collins et al, 1993; Eliopaulos et al, 1998). The two isolates of 
vancomycin-resistant K faecium with Van A and Van B genotype were susceptible 
to quinupristin/dalfopristin (MICs = 0.25 mg/L and 1 mg/L, respectively). 
However, 9% of all E. faecium isolates tested were resistant to 
quinupristin/dalfopristin (MIC90 = 1 mg/L). It is surprisingly to find so much 
resistance to quinupristin/dalfopristin in this study as the drug was not yet available 
in Hong Kong or even anywhere in the world. Although a close relative, 
pristinamycin, has been available in France for many years, this is still not 
available in Hong Kong. Reinert et al (1999) showed that their E. faecium isolates 
which habour vanA gene are susceptible to quinupristin/dalfopristin. The fact that 
95% of our E. faecalis isolates and 44% of other enterococcal species were 
resistant to quinupristin/dalfopristin suggested that the indication of this drug was 
mainly for E. faecium. 
In general, the percentage of enterococci resistant to various antibiotics in 
this study was considerably higher as compared to that in other countries. Ninety-
five percent of our E. faecium isolates were resistant to ampicillin while other 
studies reported only 50% - 78% (Huygens & Lewis, 1995; Struwig, Botha & 
Chalkley, 1998; Andrews et al, 2000). More than 20% of our enterococci exhibited 
high-level resistance to gentamicin, while in other places the figure was 14% -
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20% (Silverman et al, 1998; Reinhert et al, 1999, Schouten et al, 1999). Whether 
the large proportion of resistant strains was a result of the extensive use of 
antibiotics that exerted selective pressures to facilitate resistance gene transfer 
(Woodford et al, 1992 & Simjee & Gill, 1997) had to be elucidated by reviewing 
the amount of antibiotic consumption supplied by the hospital pharmacy. 
Although enterococci are intrinsically resistant to aminoglycosides, the 
treatment of serious enterococcal infections is the synergistic combination of a p-
lactam or glycopeptide with an aminoglycoside (Murray，1990). However, this 
synergy would be lost if high-level aminoglycoside resistance developed and such 
therapy would not be effective. Our study showed that an average of 15% of the 
enterococcal isolates were resistant to ampicillin and 25% were resistant to high 
concentrations of gentamicin. Thus, there would be a 1 in 4 chance of treatment 
failure if the standard regimen for treating serious enterococcal infections was 
used. Resistance to other drugs such as cotrimoxazole, erythromycin or 
chloramphenicol was also high so that they would also not be useful as therapeutic 
agents for enterococcal infection. However, vancomycin and teicoplanin remained 
effective as only a very small proportion of enterococci was resistant to them. 
We used PCR to detect the presence of vancomycin resistance genes in 
strains with vancomycin MICs >4 mg/L. The primers chosen were specific for 
van A, vanB, vanC-1 and vanC-2IC-3 (Dutka-Malen, Evers & Courvalin, 1995; 
Free & Sahm, 1996; Clark et al, 1998). There were only one isolate each of VanA 
and VanB resistance and both were E. faecium, while there were eight isolates of 
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E. gallinarum with VanC-1 resistance and two isolates of E. casseliflavus 
withVanC-2 resistance. The clinical significance of vanA and vanB genes has been 
well-documented (Arthur & Courvalin, 1993; Quintiliani, Evers & Courvalin, 
1993; Low, Willey & McGeer, 1995; Arthur, Reynolds & Courvalin, 1996; 
Leclercq, 1997; Murray, 1997; French, 1998). However, whether strains with 
vanC-1 and vanC-2/C-3 are clinically significant is still questionable since only 
low-level vancomycin resistance is conferred and special infection control 
procedures are usually not required (Low, Willey & McGeer，1995; Toye et al, 
1997; Clark et al, 1998). However, high-level resistance to glycopeptides has also 
been reported in E. gallinarum and E. casseliflavus (Dutka-Malen et al, 1994; 
Yoshikazu et al, 1996; Coombs et al, 1999). Thus, detection of vanA, vanB and 
vanC is recommended whenever vancomycin-resistant enterococci were isolated 
from clinical specimens (Coombs et al, 1999). 
High-level gentamicin resistance in enterococci is usually due to 
acquisition of genes coding for aminoglycoside-modifying enzymes (AMEs) that 
inactivated the activity of gentamicin. The bi-functional enzyme 6，-N- � 
acetyltransferase/2" phosphotransferase (AAC6-APH2") which mediates high-
level resistance to gentamicin and to all clinically useful aminoglycosides 
(gentamicin, tobramycin, amikacin and netimicin) except streptomycin. It is the 
most common AME detected in enterococci (Murray, 1990; Leclercq, 1997; 
Moellering, 1997). This enzyme is also commonly produced by staphylococci and 
is thought to be the origin of the enzyme in enterococci (Leclerq et al, 1992). We 
performed PCR using primers specific for aacA/aphD that codes for AAC6'-
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APH2" (van der Klundert & Vlegenthart, 1993) on all our isolates with gentamicin 
MICs >1024 mg/L. Only four of the 124 isolates tested did not habour the gene. 
This showed that most of our gentamicin-resistant enterococcal isolates were due 
to the production of AAC6'-APH2" enzyme. As van den Braak et al (1999) 
showed that enterococci can produce more than one AME, we had to confirm 
whether our isolates produced AAC6'-APH2" enzyme in addition to other 
enzymes by PCR using primers specific for these other enzymes. The mechanism 
of high-level gentamicin resistance in the four strains with no amplification 
product after PCR needs to be fiirther investigated. The resistance might be due to 
other AMEs found in enterococci such as 6-nucleotidyltransferase (ANT6), 4，-
nucleotidyltransferase (ANT4，)，3'-phosphotransferase (APH3') or APH(2") 
(Murray, 1990; Leclercq et al, 1992; Tsai et al, 1998), novel undescribed enzymes 
or resistance mechanisms other than enzyme hydrolysis. 
None of the 76 isolates of ampicillin-resistant enterococci were found to 
produce P-lactamase. This is not surprising as p-lactamase has only been detected 
rarely in enterococci (Greenwood, 1989; Gray and Pedler, 1992). Resistance to (3-
lactams is usually due to the decreased affinity of the drug to penicillin binding 
proteins. Thus, further work has to be carried out to determine whether the 
mechanism of resistance to the (3-lactam drugs was due the alteration or decreased 
affinity ofPBP5 (Fontanna et al, 1994; Rybkine et al, 1997). 
By using the breakpoint criteria for susceptible strains (NCCLS, 1999), 
only two (0.4%) out of the 498 isolates tested were susceptible to all the antibiotics 
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tested while 60% were resistant to more than three antibiotics tested. In order to 
determine there was any clonal relationship between multi-resistant enterococci, 
PFGE was used to fingerprint 42 K faecium and eight E. faecalis isolates that were 
resistant to seven to nine antibiotics. PFGE types of >85% similarity were grouped 
within one group. E. faecium isolates of the same resistance phenotypes were 
found to belong to different PFGE types or PFGE groups. Similarly, although the 
E. faecalis isolates tested were of similar resistance patterns, they belonged to 
different PFGE types or groups. Thus, there was no correlation between 
antimicrobial resistances and DNA fingerprints obtained by PFGE. Thus, these 
enterococcal infections were most probably sporadic cases and not due to spread of 
a few related strains. 
In summary, the majority of the enterococci isolated in the present study 
were E. faecalis (81%) followed by E. faecium (15%) and other enterococci (4%). 
Most of the isolates were from urine. E. faecium was generally more resistant to 
antibiotics than E. faecalis. Fifteen percent of the enterococci studied were 
resistant to ampicillin. High-level gentamicin resistance was detected in 18% and 
was due mainly to the production of AAC6'-APH2" enzyme. Two E. faecium 
isolates, one of VanA and the other of VanB phenotype were the only clinically 
significant VRE detected. Multi-resistant enterococci were shown to be 
heterogeneous by PFGE. 
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5. Future Work 
This study has opened ample opportunities for various research areas to be 
carried out in ftiture. 
1. Continuous surveillance of antimicrobial susceptibilities of enterococci should 
be performed so as to monitor the development of VRE in the hospital and in 
the community. Prompt identification of VRE in the hospital could ensure that 
strict infection control measures could be instituted to prevent the spread of the 
organism. By screening for VRE carriers in the community, the prevalence of 
VRE could be determined and the possibility of development of VRE 
infections could be predicted. 
2. At present, primers specific for genes coding for D-alanine: D-alanine (D-Ala: 
D-Ala) ligases (ddl) and D-ala-D-serine ligases were available for the 
identification of E. faecalis, E. faecium^ E. gallinarum and E. casseliflavus!E. 
flavescens only. Primers specific for enterococcal species other than these 
could be designed so that PCR could be applied for the identification for more 
enterococcal species. 
3. Only 2% of the isolates with elevated vancomycin MICs were shown to 
harbour vanA, vanB or vanC genes. Presence of vanD, vanE or new van genes 
could be investigated by using van degenerated primers. The amplified 
products could be cloned and subsequently sequenced. If a new gene was 
detected, primers could be designed for future use in PCR for this gene. 
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4. In this study, we had only investigated some of the antimicrobial resistance 
mechanisms of our enterococcal strains. Further work could be carried out to 
determine the possibility that isolates producing AAC6'-APH2" could produce 
one or more enzymes and the aminoglycoside resistance mechanisms of the 
four strains that gave no amplification products with specific primers for the 
gene coding for the bi-funetional AME (AAC6'-APH2"). Primers specific for 
genes coding for other AMEs could be used. If subsequent PCRs yielded no 
amplification products, the resistance genes could be cloned and characterized. 
Alternatively, other mechanisms of resistance such as membrane permeability 
could be investigated. 
5. None of our ampicillin-resistant enterococci produced detectable P-lactamases. 
Penicillin-binding proteins (PBPs) of these isolates could be characterized to 
determine if the resistance was due to presence of a PBPS or other new altered 
PBPs. 
6. During the incidence of VRE, we screened faecal samples of all patients in that 
particular ward where VRE was isolated to detect the present of VRE in other 
patients. VREs were isolated from other patients in the case of Van A VRE. 
Thus, we could apply the PFGE method on these isolates and investigate 
retrospectively the source and spread of the VRE. 
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